| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Dermatologic System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Biologics | Dermatologic System |
Recent Updates
Recently added Catalysts
Vanda Pharmaceuticals Inc.$6.24
-0.04 (-0.63%)
B 65Pipeline Score Undervalued Pharma · Commercial
Market Cap
372.24 M
EPS
-4.05
P/E Ratio
-
Value Trade
4.94 M
SEC Financials
Q1 2026Dilution Risk
40%Revenue
51.72 M
R&D Expenses
28.43 M
Operating CF
-50.22 M
Total Assets
433.52 M
Total Liabilities
152.76 M
Equity
280.76 M
D/E Ratio
12,345
-1.9 %
Week
-9.24 %
1 Month
2.82 %
3 Month
28.42 %
6 Month
-66.92 %
5 Year
-35.18 %
All Time
Cash Data
Cash Position
202.31 M
Monthly Burn
16.74 M
Runway
10.2 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
596.71 K
52 Week Range
4.14 - 9.94
% held by Insiders
5.43 %
% held by Institutions
77.33 %
Enterprise Value
183.00 M
Total Shares
60.10 M
Short %
13.65 %
Float Shares
53.79 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vanda Pharmaceuticals Inc.
802Total events
12Upcoming
269Tier-1 (high impact)
2010 – 2035Coverage
Upcoming catalysts 12
May 2, 2028
T1Patent Expiry
License for generic Fanapt effective May 2, 2028 if pediatric exclusivity obtained
TBD
T1AdCom Scheduled
Formal evidentiary public hearing under 21 CFR Part 12 for HETLIOZ jet lag sNDA
2026-H1
T2Trial Initiation
Phase III program start for NEREUS in GLP-1 analog-induced vomiting prevention
Event history 790
2033
▲Patent GrantedHETLIOZApprovedIP / Competition
Method to Diagnose in Non-24 patent expires 2033 (if issued)
2027
▲Patent GrantedHETLIOZApprovedIP / Competition
Tasimelteon Dose Range patent expires 2027 (if issued)
Jul 7, 2026
▲Rare Pediatric DiseaseVCA-894ADesignation
FDA granted Rare Pediatric Disease Designation for VCA-894A
Charcot-Marie-Tooth disease type 2Ssource ↗
Q3 2026
▲Product LaunchBysantiApprovedPost-Market
Commercial availability of BYSANTI expected in Q3 2026
Bipolar I Disorder and Schizophreniasource ↗
Jun 2026
◆FDA ApprovalimsidolimabFDA Decision
Potential FDA approval of imsidolimab for GPP
generalized pustular psoriasissource ↗
May 27, 2026
▲Other Regulator MilestoneimsidolimabEx-US Regulatory
MHLW grants orphan drug designation to imsidolimab for GPP
generalized pustular psoriasissource ↗
May 20, 2026
◆Oral PresentationPresentation
Vanda participates at B. Riley Securities 26th Annual Investor Conference
May 19, 2026
◆Oral PresentationPresentation
Vanda participates at HCW 4th Annual BioConnect Investor Conference fireside chat
May 12, 2026
◆Oral PresentationPresentation
Vanda participates at Bank of America Securities Global Health Care Conference 2026
May 6, 2026
◆Quarterly UpdateCorporate
Conference call to discuss Q1 2026 financial results and corporate activities
May 6, 2026
▲FDA ApprovalBysantiApprovedFDA Decision
FDA approval of BYSANTI
bipolar I disorder and schizophreniasource ↗
May 4, 2026
▲Product LaunchNEREUSApprovedPost-Market
U.S. commercial availability of NEREUS (tradipitant) for motion sickness
prevention of vomiting induced by motion in adultssource ↗
Drug Pipeline Intelligence
B65
Pipeline Score $2.5B
Pipeline ValueUndervalued
Valuation Signal14
Drugs Scored6.8x
rNPV / MCap Top 91%
Micro Cap (rank 83 of 911)
Percentile RankVanda Pharmaceuticals Inc. holds a solid B-grade pipeline (65/100), with $10.7B risk-adjusted pipeline value, led by Tradipitant in Atopic Dermatitis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tradipitant Small molecule | Nausea and Vomiting | Phase 3 | NCT07446439 | 53% | $2.9B | RECRUITING | 280 | VERY_FAST | B (65) | Dec 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
NEREUS™ | prevention of vomiting induced by GLP-1 receptor agonists | Phase 2 | 2026-04-08 | 29.3% of tradipitant-treated participants (17/58) experiencing vomiting compared to 58.6% on placebo (34/58) (p=0.0016); 50% relative reduction; 22.4% in the tradipitant group (13/58) versus 48.3% on placebo (28/58) (p=0.0039) Read More | Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists Read More | |
NEREUS™ | prevention of vomiting induced by GLP-1 receptor agonists | Phase 2 | 2026-04-08 | 29.3% of tradipitant-treated participants (17/58) experiencing vomiting compared to 58.6% on placebo (34/58) (p=0.0016); 50% relative reduction; 22.4% in the tradipitant group (13/58) versus 48.3% on placebo (28/58) (p=0.0039) Read More | Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists Read More | |
NEREUS™ | prevention of vomiting induced by GLP-1 receptor agonists | Phase 2 | 2026-04-08 | 29.3% of tradipitant-treated participants (17/58) experiencing vomiting compared to 58.6% on placebo (34/58) (p=0.0016); 50% relative reduction; 22.4% in the tradipitant group (13/58) versus 48.3% on placebo (28/58) (p=0.0039) Read More | Vanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VNDA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VNDA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VNDA▼ -0.6%today
Vanda Pharmaceuticals Announces Participation in the B. Riley Securities 2026 Mind, Muscle & Vision Summit
Vanda Pharmaceuticals Inc. has announced its participation in the B. Riley Securities Mind, Muscle & Vision Summit, scheduled for July 16, 2026, in Boston, Massachusetts. This event will feature a fireside chat, showcasing Vanda's commitment to innovative therapies. The company aims to address significant medical needs and improve patient lives.
Read more →VNDA▼ -0.6%today
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda Pharmaceuticals has received FDA Rare Pediatric Disease Designation for its investigational therapy VCA-894A, aimed at treating Charcot-Marie-Tooth disease type 2S (CMT2S). This designation highlights the serious nature of CMT2S, a rare inherited neurological disorder affecting children. The therapy targets a unique genetic variant of the disease, which has limited treatment options available.
Read more →VNDAVanda Pharmaceuticals Announces Orphan Drug Designation in Japan for Imsidolimab in Generalized Pustular Psoriasis
Vanda Pharmaceuticals has received orphan drug designation from Japan's MHLW for imsidolimab, a monoclonal antibody aimed at treating generalized pustular psoriasis (GPP). This designation offers development incentives and underscores the drug's potential to meet significant unmet medical needs in a rare disease affecting approximately 2,200 individuals in Japan. The designation follows similar recognition in the U.S., highlighting global interest in imsidolimab.
Read more →VNDA▼ -14.1%on this news
Vanda Pharmaceuticals Announces Participation at May 2026 Investor Conferences
Vanda Pharmaceuticals announced its participation in several investor conferences scheduled for May 2026. These include the Bank of America Securities Global Health Care Conference in Las Vegas, the HCW 4th Annual BioConnect Investor Conference in New York City, and the B. Riley Securities 26th Annual Investor Conference in California. The company aims to connect with investors and showcase its innovative therapies.
Read more →VNDA▼ -14.1%on this newsshared move
Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
Vanda Pharmaceuticals reported strong financial results for Q1 2026, showcasing a 26% increase in Fanapt sales and the successful launch of NEREUS. The company also received FDA approval for BYSANTI, contributing to an optimistic revenue outlook for the year. However, Vanda reported a net loss of $48.6 million, raising concerns about financial sustainability amidst ongoing product development.
Read more →VNDA▲ +8%on this newsshared move
Vanda Pharmaceuticals Announces U.S. Commercial Availability of NEREUS™ (tradipitant), the First New Pharmacologic Treatment for People with Motion Sickness in More Than 40 Years
Vanda Pharmaceuticals has announced the commercial availability of NEREUS™ (tradipitant), the first new treatment for motion sickness in over 40 years. This neurokinin-1 receptor antagonist is now accessible via traditional pharmacies and a direct-to-consumer platform. It is aimed at preventing vomiting induced by motion in adults and is priced at $85 per dose, significantly lower than the standard rate. The drug's efficacy was established through pivotal Phase 3 clinical trials, marking a historic advancement in motion sickness management.
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Vanda Pharmaceuticals Inc. will release its first quarter 2026 financial results on May 6, 2026, after market close. A conference call will follow at 4:30 PM ET to discuss the results and corporate activities. Investors can access the call via phone or through a webcast on Vanda's website.
Read more →VNDAVanda Pharmaceuticals announces the publication of "Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis" in NEJM Evidence
Vanda Pharmaceuticals has announced the publication of a pivotal phase III study on imsidolimab for Generalized Pustular Psoriasis in NEJM Evidence. This study is part of the Biologics License Application submitted to the FDA, with a target action date of December 12, 2026. Imsidolimab is a monoclonal antibody targeting IL-36 receptor signaling, with potential regulatory exclusivity extending into the late 2030s.
Read more →VNDAVanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals has appointed Dr. Charles Duncan to its Board of Directors, effective April 22, 2026. Dr. Duncan, a seasoned leader in the life sciences sector, brings nearly three decades of experience as a biotechnology equity research analyst. His expertise is expected to complement Vanda's efforts in advancing its innovative pipeline and addressing patient needs.
Read more →VNDAVanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
Vanda Pharmaceuticals has urged the FDA to withdraw a proposal from its FY 2027 budget that would extend drug review timelines and replace formal hearings with internal appeals. The company argues that this change would worsen delays and reduce transparency for patients. Vanda's CEO criticized the proposal as a move to legalize slower review processes, which could negatively impact innovation and patient access to medications.
Read more →VNDAVanda Pharmaceuticals Announces Initiation of The Thetis Study, a Clinical Trial of NEREUS™ for the Prevention of Vomiting Induced by GLP-1 Receptor Agonists
Vanda Pharmaceuticals has initiated Thetis, a clinical trial for NEREUS™ aimed at preventing vomiting in patients using GLP-1 receptor agonists. This study follows previous positive results showing NEREUS™'s effectiveness in reducing nausea and vomiting. The trial is randomized and placebo-controlled, with results expected by Q4 2026. The company aims to enhance patient adherence to GLP-1 therapies, despite potential risks in trial outcomes.
Read more →VNDAVanda Pharmaceuticals Calls for Stronger FDA Action to Accelerate Shift from Animal Testing to Human-Relevant Methods
Vanda Pharmaceuticals has expressed concerns regarding the FDA's draft guidance on New Approach Methodologies (NAMs) in drug development. While the company supports the FDA's intent to modernize testing and reduce animal use, it criticizes the draft for lacking specific examples and clear validation processes. Vanda urges the FDA to revise the guidance to better facilitate the adoption of human-relevant testing methods.
Read more →VNDAVanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals announced that the FDA has granted a formal evidentiary hearing regarding the proposed refusal of its supplemental new drug application for HETLIOZ® in treating jet lag disorder. This is a significant regulatory step, as it is the first such hearing in over 40 years. The hearing follows a court ruling that criticized the FDA's previous refusal to engage with Vanda's evidence. HETLIOZ® is currently approved for other sleep disorders, and the company aims to expand its use.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the 2026 Citizens Life Sciences Conference
Vanda Pharmaceuticals has announced its participation in the 2026 Citizens Life Sciences Conference, scheduled for March 11, 2026, in Miami. The company will deliver a corporate presentation at 2:15 p.m. Eastern Time, which can be accessed live via its corporate website. Investors are encouraged to prepare in advance for the event.
Read more →VNDAVanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Pharmaceuticals announced the FDA's acceptance of its Biologics License Application for imsidolimab, aimed at treating Generalized Pustular Psoriasis (GPP). The drug, a monoclonal antibody targeting IL-36 receptor signaling, demonstrated significant efficacy in clinical trials. If approved by the target date of December 12, 2026, it could fulfill a critical need in treating this rare disorder.
Read more →VNDA▲ +41.5%on this newsshared move
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
Vanda Pharmaceuticals has received FDA approval for BYSANTI™ (milsaperidone), a new treatment for bipolar I disorder and schizophrenia. This atypical antipsychotic offers a trusted safety profile and is based on extensive clinical data. The drug is expected to be commercially available in Q3 2026 and may also be tested for treatment-resistant major depressive disorder.
Read more →VNDA▼ -17.6%on this news
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Vanda Pharmaceuticals reported strong financial results for Q4 and full year 2025, with a notable increase in product sales driven by Fanapt. The company anticipates an FDA decision on Bysanti by February 21, 2026, which could enhance its psychiatry portfolio. Additionally, the recent FDA approval of NEREUS for motion-induced vomiting prevention is a significant achievement. However, Vanda also faced substantial net losses during the year.
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
Vanda Pharmaceuticals Inc. will announce its fourth quarter and full year 2025 financial results on February 11, 2026. A conference call is scheduled for the same day at 4:30 PM ET, where management will discuss the results and corporate activities. Investors can participate via phone or listen to the webcast on the company's website.
Read more →VNDA▼ -14.1%on this news
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has received a decision letter from the U.S. Food and Drug Administration's ...
Vanda Pharmaceuticals announced that the FDA has issued a decision letter rejecting the supplemental New Drug Application for HETLIOZ for jet lag disorder. Although the FDA recognized positive efficacy from clinical trials, it found the evidence insufficient due to the inadequacy of controlled phase advance protocols in simulating actual jet travel conditions. Vanda disagrees with this assessment and remains committed to pursuing FDA approval.
Read more →VNDA▼ -14.1%on this news
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ Supplemental New Drug Application for Jet Lag Disorder
Vanda Pharmaceuticals received a decision letter from the FDA stating that the supplemental New Drug Application for HETLIOZ intended for treating jet lag disorder cannot be approved in its current form. While the FDA recognized positive efficacy from clinical trials, it concluded that the evidence does not sufficiently demonstrate effectiveness, citing shortcomings in the trial protocols. Vanda disagrees with this determination and remains committed to collaborating with the FDA to address the concerns. They seek to advance the therapy's approval for travelers suffering from jet lag.
Read more →VNDAVanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved NEREUS™...
Vanda Pharmaceuticals has received FDA approval for NEREUS™ (tradipitant), marking a significant advancement in the treatment of motion sickness. This is the first new pharmacologic option in over four decades, supported by robust clinical trial data demonstrating its efficacy. The approval is expected to enhance the quality of life for many individuals affected by motion sickness.
Read more →VNDAVanda Pharmaceuticals Announces FDA Approval of NEREUS (tradipitant) for the Prevention of Vomiting Induced by Motion A Historic Scientific Milestone in the Prevention of Motion Sickness WASHINGTON
Vanda Pharmaceuticals announced the FDA approval of NEREUS (tradipitant) for the prevention of vomiting induced by motion, marking a significant advancement after 40 years without new pharmacological treatments for motion sickness. The drug is an oral neurokinin-1 receptor antagonist, demonstrating substantial efficacy in clinical trials with risk reductions in vomiting of over 50-70%. NEREUS is set to launch in the coming months, and Vanda is also exploring its use for other conditions, such as gastroparesis and nausea associated with GLP-1 receptor agonists.
Read more →VNDA▲ +6.4%on this news
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Vanda Pharmaceuticals has submitted a Biologics License Application (BLA) to the FDA for imsidolimab, targeting generalized pustular psoriasis (GPP). The submission is backed by positive Phase 3 trial results showing rapid disease clearance and a favorable safety profile. Vanda has requested priority review, which could lead to FDA approval as early as mid-2026.
Read more →VNDA▼ -5.6%on this newsshared move
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
Vanda Pharmaceuticals Inc. has announced its participation in the upcoming J.P. Morgan Healthcare Conference on January 15, 2026. The corporate presentation will be accessible live on the company's website, allowing investors to engage directly. This event highlights Vanda's commitment to addressing unmet medical needs through innovative therapies.
Read more →VNDAFDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Vanda Pharmaceuticals announced that the FDA has lifted the partial clinical hold on tradipitant, allowing for extended clinical studies in motion sickness. This decision followed a formal dispute resolution request and an expedited review by the FDA. The FDA concluded that tradipitant is suitable for acute motion sickness treatment, eliminating the need for additional toxicity studies. Vanda's New Drug Application for tradipitant is also progressing, with a target action date of December 30, 2025.
Read more →VNDAVanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals announced updates regarding tradipitant for motion sickness, including an expedited FDA re-review of a partial clinical hold. The completion date for this review has been extended to December 5, 2025. Additionally, the New Drug Application (NDA) review is progressing, with a target action date set for December 30, 2025, as Vanda aims to introduce a new treatment for motion sickness.
Read more →VNDA▲ +21.6%on this news
Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
Vanda Pharmaceuticals announced positive results from a clinical study of tradipitant, which successfully reduced nausea and vomiting in patients treated with the GLP-1 agonist Wegovy. The study showed a 50% reduction in vomiting rates compared to placebo. Tradipitant's favorable safety profile and efficacy position it as a significant adjunct in the expanding GLP-1 agonist market, with a Phase III program planned for 2026.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
Vanda Pharmaceuticals has announced its participation in the Stifel 2025 Healthcare Conference, scheduled for November 12, 2025, in New York City. The company will deliver a corporate presentation at 4:40 p.m. Eastern Time, which can be accessed live on its corporate website. Investors are encouraged to register in advance for the event.
Read more →VNDA▼ -20.1%on this news
Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
Vanda Pharmaceuticals reported strong financial results for Q3 2025, with net product sales reaching $56.3 million, an 18% increase from the previous year. The company is optimistic about its pipeline, with several NDAs under FDA review and a BLA submission anticipated. However, Vanda also reported a significant increase in net loss, prompting a revision of its financial guidance for the year.
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
Vanda Pharmaceuticals Inc. has announced the date for releasing its third quarter 2025 financial results, scheduled for October 29, 2025, after market close. Following the release, a conference call will be held at 4:30 PM ET where management will discuss the results and other corporate activities. The call will be accessible via phone and streamed on the company's website, with a replay available for a week following the event.
Read more →VNDAVanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration
Vanda Pharmaceuticals has announced a collaborative framework with the FDA to resolve disputes related to its products HETLIOZ® and tradipitant. This agreement is aimed at facilitating the review processes for these medications, which address significant medical needs. However, the timeline for FDA reviews remains uncertain, highlighting potential risks.
Read more →VNDAVanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomized, double-blind, placebo-controlled trial"
Vanda Pharmaceuticals announced the publication of a study in PLOS One demonstrating that HETLIOZ® significantly improves sleep latency in patients with primary insomnia. The study showed that improvements persisted over time and that the treatment did not cause cognitive or mood changes. Vanda is seeking FDA approval for HETLIOZ® to treat insomnia and other sleep disorders.
Read more →VNDAVanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
Vanda Pharmaceuticals Inc. has announced its participation in three investor conferences scheduled for September 2025. The conferences include the Cantor Global Healthcare Conference, the Wells Fargo Healthcare Conference, and the H.C. Wainwright Annual Global Investment Conference. Corporate presentations will be accessible live on Vanda's website, enhancing investor engagement.
Read more →VNDAVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals has announced that the FDA has granted Orphan Drug Designation for VGT-1849B, a novel JAK2 inhibitor designed for the treatment of polycythemia vera (PV). This designation is intended for therapies addressing rare medical conditions and provides various benefits to the developer. VGT-1849B utilizes a unique chemistry that enhances its ability to target JAK2, potentially offering a safer profile compared to existing treatments. If approved, the drug could improve treatment outcomes and the quality of life for patients suffering from PV.
Read more →VNDAVanda Seeks FDA Commissioner Review of Outgoing CDER Director
Vanda Pharmaceuticals is urging FDA Commissioner Martin Makary to review a decision made by Jacqueline Corrigan-Curay, the outgoing director of CDER, who upheld the approval of two generic versions of Vanda's drug, Hetlioz. Vanda argues that the approvals were flawed due to inadequate studies and data inconsistencies. The company has previously filed petitions against these generic approvals, highlighting potential risks to public health. Vanda's concern underscores broader issues of bias within the FDA's approval processes as they seek accountability.
Read more →VNDAIn a Major Win for Vanda, a Federal Appeals Court Overturns FDA
Vanda Pharmaceuticals secured a significant victory against the FDA in its approval process for HETLIOZ® to treat jet lag disorder. The D.C. Circuit Court found that the FDA failed to adequately engage with the evidence provided by Vanda concerning the drug's efficacy. With the court's ruling, the FDA must now either approve the supplemental New Drug Application or hold a hearing regarding its decision. This landmark case redefines the regulatory dynamics between the FDA and pharmaceutical companies, ensuring that scientific evidence is given due consideration in future evaluations.
Read more →VNDA▼ -8.8%on this news
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results Fanapt Q2 2025 net product sales increased by 27% to $29.3 million compared to Q2 2024 Bysanti TM (milsaperidone) NDA for bipolar I disorder and schizop
Vanda Pharmaceuticals reported its financial results for Q2 2025, highlighting a 27% increase in Fanapt sales to $29.3 million year-over-year. The company anticipates significant regulatory developments, including the Bysanti and Tradipitant NDAs, with action dates set for 2025 and 2026. However, it also reported a substantial increase in net loss, reaching $27.2 million for the quarter. Overall, while product sales grew, key products faced challenges in sales performance.
Read more →VNDA▼ -8.8%on this news
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2025....
Vanda Pharmaceuticals reported a 27% increase in Fanapt sales for Q2 2025, totaling $29.3 million. The company has submitted NDAs for Bysanti and Tradipitant, with PDUFA dates set for February and December 2026, respectively. However, the overall net loss rose to $27.2 million, reflecting challenges in other product sales.
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
Vanda Pharmaceuticals has announced that it will release its second quarter financial results for 2025 on July 31, 2025. The results will be disclosed prior to the market opening, and a conference call is scheduled for the same day at 8:00 AM ET for management to discuss the results and other corporate activities. The conference call will also be available as a live broadcast and archived on the company's website for future access.
Read more →VNDAVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
Vanda Pharmaceuticals has announced the first patient receiving a dose of VCA-894A, an antisense oligonucleotide aimed at treating Charcot-Marie-Tooth disease Type 2S, a rare genetic disorder. This first-in-human clinical trial focuses on the safety and tolerability of the treatment. VCA-894A specifically targets a variant of the IGHMBP2 gene, aiming to restore its functionality. The move represents a significant step towards personalized therapies for rare conditions, although the company acknowledges the uncertainties associated with clinical outcomes.
Read more →VNDAVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
Vanda Pharmaceuticals Inc. announced its inclusion in the 2025 ASCP Annual Meeting in Scottsdale, Arizona, where they will present research on Bysanti™, an atypical antipsychotic. The presentation will focus on pharmacokinetic results comparing Milsaperidone and Iloperidone. If approved, Bysanti™ is anticipated to enter the market in 2026, with a path for prolonged exclusivity extending into the 2040s.
Read more →VNDA▲ +5.9%on this news
Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
Vanda Pharmaceuticals Inc. has announced its participation in the upcoming Mizuho Neuro & Ophthalmology Summit 2025, which will take place in New York City on May 21, 2025. The company plans to engage in investor meetings during this summit, highlighting its strategic focus on neuro and ophthalmology markets. The participation reflects Vanda's commitment to connecting with stakeholders and showcasing its advancements in these fields.
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2025 Financial Results Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2025....
Vanda Pharmaceuticals reported its Q1 2025 financial results, highlighting a 14% increase in total prescriptions for Fanapt compared to the previous year. The company announced the acceptance of new drug applications for Bysanti and Tradipitant by the FDA, with target action dates set for 2026 and 2025, respectively. Despite these positive developments, Vanda experienced a significant net loss of $29.5 million, attributed to increased expenses and a decline in PONVORY sales.
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2025 Financial Results Fanapt Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024 Fanapt Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold co
Vanda Pharmaceuticals reported a strong performance for Q1 2025, characterized by significant growth in prescriptions for Fanapt, which saw a 14% increase in total prescriptions and nearly tripled new to brand prescriptions compared to the same period last year. The company also reported total net product sales reaching $50 million, up by 5% year-over-year. However, Vanda recorded a net loss of $29.5 million, primarily due to increased expenses and the impact of a licensing agreement. The pipeline also remained robust with multiple NDA filings accepted by the FDA.
Read more →VNDAVanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
Vanda Pharmaceuticals has filed a New Drug Application (NDA) for Bysanti™ (milsaperidone) with the FDA, which is set to make a decision by February 21, 2026. The NDA filing is bolstered by clinical studies that demonstrate Bysanti™'s efficacy and safety for indications including bipolar I disorder and schizophrenia. This new treatment is derived from iloperidone and is notable for its bioequivalence with it. Additionally, ongoing clinical studies could expand its indications, although stakeholders face a wait for the FDA's verdict and further study results.
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
Vanda Pharmaceuticals Inc. has announced that it will release its financial results for the first quarter of 2025 on May 7, 2025, after market close. Following the release, the company will host a conference call at 4:30 PM ET to discuss the results and corporate activities. The event will also be accessible online for investors, allowing for both live participation and replay options.
Read more →VNDAFDA Bureaucrats Unlawfully Delay Hearing on Vanda Drug and Falsely Blame Commissioner Makary and the reductions in force at FDA
Vanda Pharmaceuticals has announced that the FDA is unlawfully delaying a hearing on its drug tradipitant for gastroparesis. The agency has attributed the delay to recent staff reductions, although Vanda disputes this claim, asserting that key personnel were not affected. This delay marks a continuation of the FDA's problematic history regarding hearing requests, as it has denied such requests for new drug approvals for the past decade. Vanda's CEO is urging for a restoration of transparency and adherence to the law within the FDA.
Read more →VNDAVanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
Vanda Pharmaceuticals has announced its participation at the 2025 American Academy of Neurology Annual Meeting in San Diego. The company will present a poster on a novel therapeutic, VCA-894A, which targets a specific mutation in a patient with Charcot-Marie-Tooth disease type 2S (CMT2S). Data demonstrates that VCA-894A led to significant improvements in neuromuscular function and is seen as a breakthrough in personalized medicine. The treatment, which has received orphan designation from the FDA, is expected to be administered to the patient for whom it was specifically developed.
Read more →VNDAVanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
Vanda Pharmaceuticals announced the submission of a New Drug Application (NDA) for its drug Bysanti 20 to the FDA for the treatment of acute bipolar I disorder and schizophrenia. This submission is backed by multiple clinical studies demonstrating the drug's safety and efficacy. If approved, Bysanti 20 could potentially hit the US market in 2026, with possibilities of patent exclusivity extending into the 2040s. The company also initiated a Phase III study of Bysanti 20 for major depressive disorder, with results expected in 2026.
Read more →VNDAVanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
Vanda Pharmaceuticals Inc. has published an article detailing the development of a personalized antisense oligonucleotide (ASO) treatment, VCA-894A, for Charcot-Marie-Tooth disease type 2S (CMT2S). This article, published in Molecular Therapy Nucleic Acids, highlights how VCA-894A targets a specific IGHMBP2 variant in a patient. The therapeutic has shown significant success in preclinical models, leading to improvements in neuromuscular function, and represents a shift towards personalized medicine. VCA-894A has received orphan drug designation from the FDA and is expected for administration soon.
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt net product sales of $26.6 million, +18% compared to Q4 2
Vanda Pharmaceuticals reported significant financial results for Q4 and full year 2024, with total revenues reaching $53.2 million, a 17% increase from the previous year. Net product sales of Fanapt also saw an 18% rise, contributing to an optimistic projection of $210 to $250 million in revenues for 2025. The company is advancing its product pipeline, having submitted several regulatory applications, including for Fanapt and Bysanti. However, they reported a $4.9 million net loss in Q4 2024, along with a decline in HETLIOZ sales due to generic competition.
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
Vanda Pharmaceuticals Inc. will announce its fourth quarter and full year 2024 financial results on February 13, 2025, after market close. A conference call is scheduled for the same day at 4:30 PM ET, where management will discuss the results and other corporate activities. Investors can participate in the call and will have access to a replay afterward. This announcement indicates Vanda's ongoing communication with shareholders regarding its financial performance.
Read more →VNDAVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Vanda Pharmaceuticals has entered into an exclusive global license agreement with AnaptysBio for the development and commercialization of imsidolimab, an IL-36R antagonist. Imsidolimab has successfully completed two global Phase 3 studies in patients with Generalized Pustular Psoriasis (GPP). Vanda plans to submit BLA and MAA applications in the US and EU while expecting to commercialize the drug soon. Anaptys will receive a $15 million payment along with royalties from future sales, highlighting the financial dynamics involved in the agreement.
Read more →VNDAVanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
Vanda Pharmaceuticals has requested a hearing regarding the FDA's rejection of its New Drug Application for tradipitant, aimed at treating gastroparesis. The FDA determined substantial evidence of efficacy was lacking, leading to a Complete Response Letter. Vanda disputes this conclusion, stressing the drug's positive results in certain studies and the legal obligations of the FDA in its review process. The company continues to advocate for the efficacy of tradipitant, citing patient responses in an ongoing expanded access program.
Read more →VNDAVanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) letter to FDA Commissioner highlights faulty gastroparesis NDA review. As previously reported,...
Vanda Pharmaceuticals Inc. has expressed significant concerns regarding the FDA's review process for its New Drug Application (NDA) for tradipitant, aimed at treating gastroparesis. The FDA previously issued a Complete Response Letter (CRL) denying the application, which Vanda describes as lacking reasoned explanations and not engaging adequately with the evidence submitted. In a letter to FDA Commissioner Robert Califf, Vanda critiques the agency's decision-making transparency and the troubling decline in advisory committee meetings, emphasizing the need for public oversight in drug application reviews. Vanda seeks a reconsideration of their application process to enhance alignment with scientific principles and public accountability.
Read more →VNDAVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
Vanda Pharmaceuticals announced that the FDA granted Orphan Drug Designation for VGT-1849A, a selective antisense oligonucleotide targeting JAK2, intended for treating polycythemia vera (PV). PV is a rare hematologic malignancy characterized by excessive red blood cell production due to a mutation in the JAK2 gene. VGT-1849A offers potential advantages over existing treatments by specifically inhibiting JAK2, thereby reducing unwanted side effects associated with broader JAK inhibition. The development underscores Vanda's commitment to precision medicine in hematological disorders, with clinical trials for this and another candidate set to begin soon.
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
Vanda Pharmaceuticals Inc. has announced its participation in two key investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference on November 19 and hold a fireside chat at the Jefferies 2024 London Healthcare Conference on November 21. Both events will be available for live remote access via Vanda's corporate website, allowing investors to participate and view the discussions.
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2024 Financial Results Revenues for Q3 2024 were $47.7 million, an increase of 23% compared to Q3 2023 Financial Guidance revised for Full Year 2024, raising the midpoint of re
Vanda Pharmaceuticals reported its financial results for the third quarter of 2024, highlighting a revenue increase of 23% year-over-year to $47.7 million. The commercial launch of Fanapt for bipolar I disorder showed positive initial market response, with new patient starts increasing by over 90%. However, the company also noted a net loss compared to a profit in the same quarter last year and a significant decline in HETLIOZ sales due to generic competition. The company plans to submit several New Drug Applications in the near future to expand its product portfolio.
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
Vanda Pharmaceuticals Inc. has announced that it will release its third quarter financial results for 2024 on November 6, 2024, after market close. A conference call will follow at 4:30 PM ET on the same day, where the management will discuss the financial results and corporate activities. The call will be available via dial-in and will also be broadcast on Vanda's website, where a replay will be accessible until November 13, 2024.
Read more →VNDA▲ +8.3%on this news
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from ...
Vanda Pharmaceuticals has received a second unsolicited proposal from Cycle Group to acquire the company for $8.00 per share. The Board of Directors has unanimously rejected this proposal, stating it undervalues the company and is not in the best interests of its stockholders. Vanda's management remains confident in its growth potential and cash position.
Read more →VNDA▲ +8.3%on this news
Vanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd. Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or S
Vanda Pharmaceuticals confirmed the receipt of a second unsolicited proposal from Cycle Group Holdings Ltd. to acquire the company at $8.00 per share. After thorough evaluation, Vanda's Board of Directors unanimously rejected the offer, citing that it undervalues the company and is not aligned with the interests of stockholders. The Board expressed confidence in Vanda's growth prospects, strong cash reserves, and clinical pipeline, asserting better long-term value creation than the proposed acquisition price.
Read more →VNDA▼ -6.1%on this news
FDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its tradipitant development program. On September 18, 2024, the U.S....
Vanda Pharmaceuticals announced that the FDA has declined to approve its New Drug Application for tradipitant, intended for treating gastroparesis symptoms. The FDA issued a Complete Response Letter, suggesting further studies that Vanda believes are inappropriate. Despite this setback, Vanda maintains that their application meets the efficacy standards and plans to pursue further marketing authorization.
Read more →VNDA▼ -6.1%on this news
FDA Declines to Approve Vanda s Marketing Application for Tradipitant in Gastroparesis WASHINGTON
Vanda Pharmaceuticals announced that the FDA has declined to approve its New Drug Application for tradipitant, intended for treating gastroparesis. The decision was communicated through a Complete Response Letter that criticized the evidence provided and called for additional studies. Vanda disputes the FDA's conclusions and emphasizes the drug's efficacy for patients suffering from severe symptoms. The company plans to continue its efforts to gain marketing authorization and support existing patients through an expanded access program.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the 2024 Cantor Global Healthcare Conference
Vanda Pharmaceuticals Inc. has announced its participation in the 2024 Cantor Global Healthcare Conference scheduled for September 19, 2024, in New York City. A fireside chat will take place at 8:00 a.m. Eastern Time, which investors can access live on the company's corporate website. Attendees are advised to register early and may access an archived version of the conference online for approximately 30 days post-event.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference
Vanda Pharmaceuticals Inc. announced its participation in the H.C. Wainwright Global Investment Conference scheduled for September 10, 2024, in New York City. The company has slated a corporate presentation for 2:00 p.m. Eastern Time, with live access available through its corporate website. Investors are encouraged to prepare in advance for the event, which underscores the company's commitment to engaging with the investment community.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the Wells Fargo 2024 Healthcare Conference
Vanda Pharmaceuticals Inc. has announced its participation in the Wells Fargo 2024 Healthcare Conference scheduled for September 6, 2024, in Boston. A corporate presentation will take place at 11:00 a.m. Eastern Time, which can be accessed live on Vanda's corporate website. Investors are encouraged to prepare in advance by visiting the conference site early to ensure proper setup. An archived version of the conference will be available on Vanda's website for approximately 30 days post-event.
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2024 Financial Results Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 Financial Guidance reinstated
Vanda Pharmaceuticals reported financial results for Q2 2024, revealing revenues of $50.5 million, a 10% increase compared to the same quarter last year. The company reinstated its financial guidance for the full year 2024, highlighting upcoming commercial launches of Fanapt for bipolar disorder and PONVORY for multiple sclerosis in Q3 2024. Despite these positive developments, Vanda faced a net loss of $4.5 million in Q2 2024, contrasting with net income during the previous year. Additionally, the company experienced declines in sales of HETLIOZ due to generic competition and an overall decrease in total net product sales compared to 2023.
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2024 Financial Results on July 31, 2024
Vanda Pharmaceuticals has announced that it will release its financial results for the second quarter of 2024 on July 31, 2024, after market close. A conference call is scheduled for the same day at 4:30 PM ET to discuss these results and other corporate activities. Investors are encouraged to prepare in advance if they wish to participate in the call, which will also be accessible via Vanda's website. A replay of the call will be available for a limited time after the event.
Read more →VNDAFederal Court Allows Vanda
Vanda Pharmaceuticals Inc. announced that the U.S. District Court for the District of Delaware has allowed its patent lawsuit against Teva Pharmaceuticals and Apotex to proceed. The Court denied the defendants' motions for judgment on the pleadings, concluding that the claims need further development. Vanda intends to continue with discovery and seek a ruling that stops the marketing of generic versions of its product, HETLIOZ, until the patent expires. This legal decision may strengthen Vanda's position in the market while they pursue enforcement of their patent rights.
Read more →VNDA▼ -5.8%on this news
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders WASHINGTON
Vanda Pharmaceuticals announced that its Board of Directors has rejected unsolicited takeover proposals from Cycle Group Holdings Ltd and Future Pak, LLC, determining that these offers significantly undervalue the company. The Board, following consultations with independent advisors, expressed confidence in Vanda's intrinsic value, business pipeline, and market position. Vanda's management is optimistic about the company's potential for long-term growth and has advised shareholders that no action is required regarding the proposals.
Read more →VNDA▼ -5.8%on this news
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are Not in the Best Interests of the Company and its Shareholders Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board"), following careful review and...
Vanda Pharmaceuticals' Board of Directors has rejected unsolicited takeover proposals from Cycle Group Holdings and Future Pak, citing that the offers substantially undervalue the company. The Board emphasized Vanda's strong financial position and growth potential, asserting that the proposals do not align with the company's intrinsic value. Shareholders are advised that no action is required at this time.
Read more →VNDA▲ +9.8%on this news
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak No Shareholder Action Required at This Time WASHINGTON
Vanda Pharmaceuticals Inc. has confirmed the receipt of a revised unsolicited takeover proposal from Future Pak, LLC, offering to acquire the company for between $8.50 and $9.00 per share in cash, along with certain Contingent Value Rights. The Board of Vanda will evaluate the proposal in consultation with its financial and legal advisors. There is no action required from shareholders at this time, and further comments will be withheld until the review is completed.
Read more →VNDA▲ +9.8%on this news
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received a revised unsolicited proposal from Future...
Vanda Pharmaceuticals has confirmed receipt of a revised unsolicited takeover proposal from Future Pak, offering between $8.50 and $9.00 per share in cash. The Board of Vanda will review this non-binding proposal in consultation with financial and legal advisors. Shareholders are advised that no action is required at this time.
Read more →VNDA▲ +24.2%on this news
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. No Shareholder Action Required at This Time WASHINGTON
Vanda Pharmaceuticals has confirmed the receipt of an unsolicited, non-binding offer from Cycle Group Holdings Ltd. to acquire the company at $8.00 per share in cash. The Vanda Board of Directors will review this offer in consultation with financial and legal advisors. No shareholder action is required at this time, and further comments will be withheld until the Board has completed its evaluation.
Read more →VNDA▲ +24.2%on this news
Vanda Pharmaceuticals Confirms Receipt of Unsolicited, Non-Binding Indication of Interest from Cycle Group Holdings Ltd. Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it has received an unsolicited, non-binding indication of...
Vanda Pharmaceuticals has received an unsolicited, non-binding acquisition offer from Cycle Group Holdings for $8.00 per share. The Board of Directors will review this proposal in consultation with financial and legal advisors. No action is required from shareholders at this time, and further comments will be withheld until the review is complete.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the Jefferies 2024 Global Healthcare Conference
Vanda Pharmaceuticals has announced its participation in the upcoming Jefferies 2024 Global Healthcare Conference, scheduled for June 6 in New York City. The company will deliver a corporate presentation at 2:00 p.m. Eastern Time, which will be accessible via its corporate website. Investors are encouraged to log in early for registration and software installation. An archived link to the presentation will be available on Vanda's site for about 30 days post-conference.
Read more →VNDAVanda Pharmaceuticals Announces Completion of Transfer of FDA Marketing Authorization for PONVORY®
Vanda Pharmaceuticals has successfully completed the transfer of FDA marketing authorization for its product PONVORY® from Johnson & Johnson, allowing Vanda to begin commercialization efforts in the U.S. PONVORY® is approved for the treatment of relapsing forms of multiple sclerosis. The company has outlined plans to launch the drug in the third quarter of 2024 and will implement marketing strategies aimed at healthcare providers. However, uncertainties remain regarding the execution of these plans and the potential outcomes of clinical trials for other inflammatory disorders.
Read more →VNDAVanda Pharmaceuticals Announces Presentations at SLEEP 2024
Vanda Pharmaceuticals Inc. has announced its participation in SLEEP 2024, taking place in Houston, TX from June 1 to June 5, 2024. The company will present several studies led by Dr. Sandra Paulina Smieszek, focusing on topics such as genetic variants linked to sleep disorders and CRISPR screening of HCN channels. These presentations underscore Vanda's ongoing research efforts in sleep medicine and genetics. Additional details about the sessions can be found on the SLEEP 2024 website.
Read more →VNDA▲ +6.5%on this newsshared move
Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Company's Board of Directors (the "Board") carefully reviewed the revised...
Vanda Pharmaceuticals' Board of Directors has unanimously rejected a revised unsolicited takeover proposal from Future Pak, citing that it undervalues the company and poses significant risks. The Board believes Vanda's strong cash position and growth potential far exceed the offer. Shareholders are advised that no action is required at this time.
Read more →VNDA▲ +6.5%on this newsshared move
Vanda Pharmaceuticals Board of Directors Determines that Revised Unsolicited Takeover Proposal is Not in the Best Interests of the Company and its Shareholders WASHINGTON
Vanda Pharmaceuticals' Board of Directors has unanimously rejected a revised unsolicited takeover proposal from Future Pak, LLC, citing that it undervalues the company. The Board concluded that the offer of $7.25 to $7.75 per share, which includes Contingent Value Rights, creates significant risks and is not in the best interests of shareholders. The Board insists on Vanda's strong financial position and operational efficiency, reinforcing its belief in the company's capacity for long-term growth. There are currently no required actions for shareholders.
Read more →VNDAVanda Pharmaceuticals Reports Positive Results from a Second Phase III Study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals reported positive results from its second Phase III study of tradipitant for motion sickness, confirming the efficacy of the drug. Both 170 mg and 85 mg dosages of tradipitant significantly reduced vomiting compared to placebo, in a study involving 316 participants at sea. A New Drug Application is planned for submission to the FDA in Q4 2024. Despite the positive outcomes, Vanda faces a partial clinical hold on longer protocols and must navigate the complexities of the FDA approval process.
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2024 Financial Results Revenues for Q1 2024 were $47.5 million, an increase of 5% compared to Q4 2023 Cash increase of $5.9 million in Q1 2024 to $394.1 million Fanapt approved
Vanda Pharmaceuticals reported first quarter 2024 financial results, with revenues of $47.5 million showing a 5% increase from the previous quarter. The company announced the FDA approval of Fanapt for the acute treatment of bipolar I disorder, set to launch commercially in Q3 2024. Despite the positive revenue growth, total net product sales saw a notable decline of 24% compared to the same quarter last year. Vanda's net loss for the quarter amounted to $4.1 million, highlighting financial challenges amidst new product developments and impending NDA submissions.
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 8, 2024
Vanda Pharmaceuticals announced that it will release its financial results for the first quarter of 2024 on May 8, 2024, after market closure. A conference call is set to be held at 4:30 PM ET on the same day, where company management will discuss these results and broader corporate activities. Investors are encouraged to participate by calling in or accessing the live webcast through Vanda's website.
Read more →VNDA▼ -6.1%on this news
Vanda Pharmaceuticals Reacts to U.S. Supreme Court
Vanda Pharmaceuticals announced that the U.S. Supreme Court has declined to hear their appeal regarding the litigation around HETLIOZ® against Teva Pharmaceuticals and Apotex. The company's CEO expressed disappointment but acknowledged the importance of the case in influencing patent law. Vanda remains hopeful that future cases can address these significant issues for the benefit of the industry and public health.
Read more →VNDA▲ +29.4%on this newsshared move
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today announced that its Board of Directors (the "Board") has adopted a limited...
Vanda Pharmaceuticals has adopted a limited duration stockholder rights plan to safeguard stockholder interests following an unsolicited acquisition proposal from Future Pak. The board determined that the proposal undervalues the company, which has a strong clinical pipeline and cash reserves. The plan aims to prevent any entity from gaining control without proper compensation to all stockholders.
Read more →VNDA▲ +29.4%on this newsshared move
Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
Vanda Pharmaceuticals has rejected several unsolicited takeover proposals from Future Pak, citing they significantly undervalue the company. The most recent proposal extended an offer of $7.25 to $7.75 per share, which the Board finds not in the best interests of shareholders. The company's strategic review highlighted its robust pipeline, strong cash position, and promising growth prospects. There is currently no action required from shareholders regarding these proposals.
Read more →VNDA▲ +29.4%on this newsshared move
Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan WASHINGTON
Vanda Pharmaceuticals has adopted a limited duration stockholder rights plan to protect its stakeholders and enhance company value. This decision comes in response to an unsolicited acquisition offer from Future Pak, LLC, which Vanda's board deemed as significantly undervaluing the company. The rights plan enables stockholders to potentially benefit from any value realization while providing the board with the means to manage any unsolicited acquisition attempts. The plan is active for one year and applies to current and future stockholders equally.
Read more →VNDA▼ -5.1%on this news· ran to +23% by day 1
Vanda Pharmaceuticals Fanapt (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder Fanapt Treatment is Now Available to Adult Patients for the Acute Treatment of Manic or Mixed Episodes A
Vanda Pharmaceuticals announced that the U.S. FDA has approved its drug Fanapt (iloperidone) for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. This marks a significant expansion of Fanapt’s indications beyond its previous use for schizophrenia. The approval suggests a promising addition to treatment options for bipolar disorder, which affects a significant portion of the adult population in the U.S. The decision is based on a pivotal study showing substantive improvement over placebo in treated patients.
Read more →VNDA▼ -5.1%on this news· ran to +23% by day 1
Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved Fanapt® (iloperidone) ...
Vanda Pharmaceuticals has received FDA approval for Fanapt® (iloperidone) to treat acute manic or mixed episodes in adults with bipolar I disorder. This approval adds a significant indication to Fanapt's existing use for schizophrenia, enhancing its commercial potential. The decision was based on a pivotal study demonstrating significant efficacy compared to placebo.
Read more →VNDA▼ -5.6%on this news
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ in the Treatment of Insomnia WASHINGTON
Vanda Pharmaceuticals announced it has received a Complete Response Letter (CRL) from the FDA regarding its supplemental New Drug Application (sNDA) for HETLIOZ, intended for treating insomnia related to sleep initiation difficulties. The CRL signifies that the FDA cannot approve the sNDA in its present form due to identified deficiencies. Vanda is currently reviewing the CRL and considering its next steps in addressing the issues highlighted by the FDA.
Read more →VNDA▼ -5.6%on this news
Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on March 4, 2024, it received a Complete Response Letter (CRL) from the U.S....
Vanda Pharmaceuticals announced that it received a Complete Response Letter from the FDA regarding its supplemental New Drug Application for HETLIOZ in treating insomnia. The FDA's letter indicates that the application cannot be approved in its current form due to identified deficiencies. Vanda is currently reviewing the CRL and considering its next steps.
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results Full year 2023 revenues were $192.6 million PONVORY acquisition completed in Q4 2023 and transition ongoing 3 FDA PDUFA target action date
Vanda Pharmaceuticals reported its financial results for Q4 and full year 2023, revealing total revenues of $192.6 million, a 24% decrease from 2022. The company successfully completed the acquisition of PONVORY but experienced a significant net loss in Q4 2023. Looking ahead, Vanda has three key FDA PDUFA action dates lined up for 2024, focusing on insomnia, bipolar disorder, and gastroparesis, amidst ongoing challenges in the commercial landscape. Despite decreased net product sales, the company maintains a strong cash reserve of approximately $388 million.
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended...
Vanda Pharmaceuticals reported its financial results for Q4 and full year 2023, revealing a total revenue of $192.6 million, a 24% decrease from 2022. The company faced challenges, including a net loss of $2.4 million in Q4. Despite these setbacks, Vanda completed the acquisition of PONVORY and has three FDA PDUFA dates scheduled for 2024.
Read more →VNDAVanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on February 4, 2024, it received a notification from the U.S. Food and Drug...
Vanda Pharmaceuticals announced that the FDA has identified deficiencies in its supplemental NDA for HETLIOZ, which treats insomnia. The FDA's notification prevents further discussion on labeling and postmarketing commitments. Vanda argues that the FDA has not adhered to the required timelines for application review, raising concerns about regulatory compliance.
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
Vanda Pharmaceuticals has announced that it will release its fourth quarter and full year financial results for 2023 on February 7, 2024. The release will occur after market close, followed by a conference call at 4:30 PM ET that same day, where management will discuss the results and corporate activities. A replay of the call will be available for a week after the event. This initiative reflects Vanda's commitment to keeping investors informed about its financial performance.
Read more →VNDAVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
Vanda Pharmaceuticals has announced that the FDA has approved its Investigational New Drug application for VTR-297, which is being developed to treat onychomycosis, a fungal nail infection. This represents a major step forward in addressing a condition that affects a significant portion of the population and for which there have been no new treatments in recent years. VTR-297 is a small molecule histone deacetylase inhibitor demonstrating antifungal activity. As Vanda begins clinical studies, there is optimism about the potential for this drug in the market.
Read more →VNDACourt Orders FDA to Resolve Vanda Pharmaceuticals
Vanda Pharmaceuticals has secured a court ruling against the FDA for unlawful delays in the review of its supplemental new drug application for HETLIOZ®, aimed at treating jet lag disorder. The United States District Court for the District of Columbia found that the FDA violated statutory timelines required for drug approvals. As a result, the court has mandated that the FDA must resolve the sNDA or initiate a hearing by March 5, 2024. This decision highlights serious issues in FDA regulation that affect drug innovation and patient access to therapies.
Read more →VNDAVanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
Vanda Pharmaceuticals has received a notice of allowance from the U.S. Patent and Trademark Office for its PONVORY patent application, which includes methods for managing multiple sclerosis treatment. This patent is expected to expire on October 10, 2042. Vanda plans to list the patent in the FDA's Orange Book once issued. PONVORY is already FDA-approved for various forms of multiple sclerosis. However, there are cautions about the uncertainties involved in the patent issuance process and market risks.
Read more →VNDAVanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal
Vanda Pharmaceuticals announced the publication of a pivotal phase III study on tradipitant's efficacy for diabetic and idiopathic gastroparesis in a peer-reviewed journal. The study's findings will support the company's New Drug Application already submitted to the FDA, which has set a target action date of September 18, 2024. However, there's a current partial clinical hold on tradipitant protocols longer than 12 weeks, which might affect its development timeline.
Read more →VNDAVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Vanda Pharmaceuticals has received FDA approval to proceed with the investigational new drug VCA-894A, aimed at treating Charcot-Marie-Tooth disease type 2S (CMT2S), a rare inherited neuropathy linked to mutations in the IGHMBP2 gene. The approval marks a significant step towards personalized medicine, as VCA-894A targets specific genetic variants affecting patients. CMT2S is characterized by muscle weakness and sensory impairment, and currently, there are no available treatments. Vanda's new drug represents hope for affected individuals, potentially improving their quality of life.
Read more →VNDAFederal Court Allows Vanda Pharmaceuticals
Vanda Pharmaceuticals has achieved a significant legal victory as the United States Court of Federal Claims allowed part of its lawsuit against the United States to proceed. The case pertains to Vanda's claims of an uncompensated taking of its trade secrets by the FDA. This ruling permits Vanda to continue seeking compensation while entering the discovery phase of the litigation. The implications of this case could greatly impact Vanda's operations and the broader pharmaceutical landscape.
Read more →VNDAVanda Pharmaceuticals announces the publication of Efficacy and Safety of Iloperidone in Bipolar Mania: A Double-Blind, Placebo-Controlled Study in the Journal of Clinical Psychiatry
Vanda Pharmaceuticals has published a pivotal study on the efficacy and safety of Iloperidone for treating bipolar mania in the Journal of Clinical Psychiatry. The findings are part of a supplemental New Drug Application for Fanapt® recently submitted to the FDA. The regulatory body has set an action date of April 2, 2024, for the review of this application, which highlights the potential significance of Iloperidone in addressing bipolar I disorder in adults.
Read more →VNDAVanda Pharmaceuticals Comments on FDA
Vanda Pharmaceuticals submitted a comment letter to the FDA concerning a new draft guidance that significantly restricts how drug manufacturers can communicate about FDA-approved drugs. The company argues that these restrictions pose threats to the First Amendment rights of drugmakers, hinder the dissemination of scientific information, and overextend the FDA's regulatory authority regarding off-label communications. Vanda emphasizes that clear standards should govern such communications, advocating for transparency and due process in the regulatory framework.
Read more →VNDAVanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY® (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has acquired U.S. and Canadian rights to PONVORY® (ponesimod) from Actelion ...
Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to PONVORY (ponesimod) from Actelion Pharmaceuticals. PONVORY is FDA-approved for treating relapsing forms of multiple sclerosis and has demonstrated superior efficacy compared to existing treatments. The acquisition is expected to enhance Vanda's portfolio and offers potential for treating various autoimmune disorders.
Read more →VNDAVanda Pharmaceuticals Acquires U.S. and Canadian Rights to PONVORY (ponesimod), a Selective S1P1R Modulator Approved for Patients with Relapsing Multiple Sclerosis WASHINGTON
Vanda Pharmaceuticals has acquired the U.S. and Canadian rights to PONVORY (ponesimod) from Actelion Pharmaceuticals. This selective S1P1R modulator is approved for treating relapsing forms of multiple sclerosis and has demonstrated a strong safety record over a decade. The acquisition is viewed as a pivotal development for Vanda, enhancing its product offerings and potential market reach. Additionally, PONVORY is reported to have therapeutic potential for various autoimmune diseases, broadening its application beyond multiple sclerosis.
Read more →VNDAVanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis
Vanda Pharmaceuticals has received acceptance from the FDA for its New Drug Application (NDA) for tradipitant, aimed at treating gastroparesis symptoms. This marks a critical step as tradipitant could become the first new treatment for the condition in over 40 years. The FDA's target decision date is set for September 18, 2024. The application includes human-relevant preclinical data, reflecting a shift towards non-animal testing methodologies. Gastroparesis affects an estimated 6 million patients in the U.S., underscoring the need for innovative therapies.
Read more →VNDA▼ -21.9%on this news
Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences
Vanda Pharmaceuticals Inc. has announced its participation in two upcoming investor conferences in November 2023, specifically the Stifel 2023 Healthcare Conference and the Jefferies 2023 London Healthcare Conference. The company will provide corporate presentations at both events, which will be accessible live via Vanda's corporate website. Investors are encouraged to register in advance and will have the opportunity to view archived presentations for 30 days following the events.
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2023 Financial Results Total revenues in the first nine months of 2023 were $147.4 million Vanda provides update on pipeline advancements and regulatory plans WASHINGTON
Vanda Pharmaceuticals, Inc. reported its third-quarter financial results for 2023, showing a total net product sales decline to $38.8 million, a 41% decrease from the previous year. Despite the revenue drop due to the at-risk launch of a generic HETLIOZ product, the company announced upcoming FDA decisions on two supplemental NDAs related to bipolar disorder and insomnia, expected in the first half of 2024. Vanda also aims to diversify its revenue sources while facing challenges in providing financial guidance amid market uncertainties.
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2023 Financial Results Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2023....
Vanda Pharmaceuticals reported its third-quarter financial results for 2023, revealing total revenues of $147.4 million for the first nine months, a 22% decrease from the previous year. The company anticipates FDA decisions on supplemental New Drug Applications for bipolar I disorder and insomnia in early 2024. Despite challenges from a generic competitor, Vanda aims to diversify its revenue through new products and indications.
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023
Vanda Pharmaceuticals has announced that it will release its financial results for the third quarter of 2023 on November 8, 2023, after the market closes. The company will host a conference call at 4:30 PM ET the same day to discuss these results and other corporate activities. Investors can join the call and access a replay via provided phone numbers and the company's website.
Read more →VNDAVanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation
Vanda Pharmaceuticals announced plans to petition the U.S. Supreme Court regarding the invalidation of its HETLIOZ® patents. The company argues that the Federal Circuit used a flawed standard of obviousness in its ruling. Vanda seeks to demonstrate that this interpretation undermines crucial patent rights essential for fostering pharmaceutical research. The company expects to file the petition by January 12, 2024, following a time extension granted by Chief Justice Roberts.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit
Vanda Pharmaceuticals Inc. has announced its upcoming participation in the Jefferies Inaugural Biotech CNS/Neuro Summit, scheduled for October 11, 2023, in New York City. A corporate presentation will take place at 1:30 p.m. Eastern Time, which can be accessed live via the company's website. Furthermore, an archived version of the presentation will be available for approximately 30 days following the event, providing additional opportunities for investor engagement.
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2023 Financial Results Q2 2023 total revenues were $46.1 million Total revenues in the first six months of 2023 were $108.6 million Vanda provides update on pipeline advanceme
Vanda Pharmaceuticals reported its financial and operational results for the second quarter of 2023. The company achieved total revenues of $46.1 million for Q2 and $108.6 million for the first half of the year, although net product sales experienced a decline compared to the previous year due to competition from generic versions of HETLIOZ. Vanda is pursuing FDA approvals for several of its products, including Fanapt and tradipitant, and reported an increase in net income compared to last year, although uncertainties remain for future financial guidance.
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2023 Financial Results Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2023....
Vanda Pharmaceuticals reported its Q2 2023 financial results, showing total revenues of $46.1 million, a 28% decrease from the previous year. The company continues to face challenges due to the at-risk launch of a generic version of HETLIOZ, impacting sales significantly. However, Vanda has made progress in its pipeline, including positive Phase III results for Fanapt in bipolar disorder and ongoing efforts for FDA approvals.
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023
Vanda Pharmaceuticals Inc. has announced that it will release its financial results for the second quarter of 2023 on July 27, 2023. Following this announcement, the company will hold a conference call at 4:30 PM ET on the same day to discuss the financial results and other corporate activities. The details for joining the call have been provided, including domestic and international dial-in numbers. A replay of the call will be available after the event, permitting access until August 3, 2023.
Read more →VNDAVanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference
Vanda Pharmaceuticals Inc. has announced its participation in the Jefferies 2023 Global Healthcare Conference, which will be held in New York City on June 9, 2023. The company is scheduled to present at 12:15 p.m. Eastern Time. Investors can access the presentation live through Vanda's corporate website, where an archived version will also be available for a month post-conference. This participation serves as an opportunity for Vanda to connect with investors and enhance its visibility in the healthcare market.
Read more →VNDAVanda Pharmaceuticals Announces Presentations at SLEEP 2023
Vanda Pharmaceuticals Inc. has announced its participation in SLEEP 2023, taking place in Indianapolis from June 3 to 7, 2023. The company will present multiple studies, including genetic research on delayed sleep phenotypes and the effects of iloperidone on sleep symptoms in bipolar patients. Featuring presentations by Dr. Sandra Paulina Smieszek, these studies aim to enhance understanding of sleep disorders. This active participation illustrates Vanda's commitment to advancing knowledge in sleep medicine.
Read more →VNDAVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
Vanda Pharmaceuticals has announced that the U.S. FDA has granted Orphan Drug Designation for VCA-894A, aimed at treating the rare Charcot-Marie-Tooth disease, Type 2S. This designation is significant as it supports the development of tailored treatments that target specific genetic variants. CMT2S is characterized by early childhood onset and progressive muscle weakness, leading to severe impairments. The innovative antisense oligonucleotide, VCA-894A, targets genetic mutations within the IGHMBP2 gene, which are crucial in the pathology of this rare disorder.
Read more →VNDAVanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness
Vanda Pharmaceuticals announced positive results from its Phase III study of tradipitant for motion sickness. The study demonstrated that both 170 mg and 85 mg doses of tradipitant significantly reduced vomiting in participants compared to placebo. Conducted in real-world conditions on boats, the study involved 365 participants. Vanda plans to pursue FDA approval following further clinical studies, as no new motion sickness medication has been approved in over 40 years.
Read more →VNDAVanda Pharmaceuticals Responds to Ruling in HETLIOZ ANDA Appeal WASHINGTON
Vanda Pharmaceuticals Inc. has responded to a recent ruling from the United States Court of Appeals, which affirmed a December 2022 decision invalidating several of its patents related to HETLIOZ. In light of the ruling, Vanda is considering whether to request a rehearing. Despite the setback in the U.S., HETLIOZ remains approved in the European Union and is unaffected by the current litigation. This development raises concerns about Vanda's market position regarding potential generic competition for HETLIOZ.
Read more →VNDA▲ +7.5%on this news
Vanda Pharmaceuticals Announces Presentations at DDW 2023
Vanda Pharmaceuticals Inc. announced its participation in Digestive Disease Week (DDW) 2023, occurring from May 6-9 in Chicago and online. The company will present several research posters focused on gastroparesis, including studies on the efficacy of Tradipitant. Notable presentations will be led by Dr. Sandra Paulina Smieszek and Dr. Jesse L. Carlin, highlighting innovative research in this therapeutic area.
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2023 Financial Results Q1 2023 total revenues were $62.5 million Vanda provides update on three upcoming regulatory submissions WASHINGTON
Vanda Pharmaceuticals reported its financial results for the first quarter of 2023, showing a 4% increase in total revenues to $62.5 million and achieving a net income of $3.3 million compared to a net loss in the prior year. The company highlighted ongoing efforts to prepare three regulatory submissions while addressing challenges related to intellectual property. Fanapt's Phase III clinical study results were positive, contributing to the outlook on the product pipeline. However, Vanda faces uncertainties regarding HETLIOZ sales due to generic competition and ongoing litigation.
Read more →VNDAVanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information
Vanda Pharmaceuticals Inc. has initiated legal action against the federal government, claiming that the FDA improperly shared confidential information from its drug master files with generic manufacturers during their review process. The company alleges this misappropriation constitutes an 'uncompensated taking' of its trade secrets related to its products HETLIOZ® and Fanapt®. Filed in the United States Court of Federal Claims, Vanda seeks economic damages as a result of these actions.
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
Vanda Pharmaceuticals Inc. has announced that it will release its financial results for the first quarter of 2023 on May 3, 2023, after the market closes. A conference call will follow at 4:30 PM ET to discuss the results and corporate activities. Investors are invited to participate and can access the conference call via a dedicated number. A replay of the call will be available for a limited time after the event.
Read more →VNDAVanda Prevails in Jet Lag Litigation Against the FDA
Vanda Pharmaceuticals Inc. achieved a legal victory against the FDA in a Freedom of Information Act case regarding its drug Hetlioz for jet lag disorder. A federal court granted judgment in favor of Vanda, compelling the FDA to disclose records related to the company's supplemental New Drug Application. The ruling rejected the FDA's argument that such disclosure would cause foreseeable harm, emphasizing the need for transparency in the approval process for new therapeutics. Vanda's president highlighted the importance of this ruling for drug innovation and public health.
Read more →VNDAVanda Pharmaceuticals Appoints Dr. Tage Honor to its Board of Directors WASHINGTON
Vanda Pharmaceuticals announced the appointment of Dr. Tage Honor to its Board of Directors, effective March 15, 2023. Dr. Honor brings a wealth of experience from his previous executive roles at prominent companies like Novo Nordisk and Novartis. He is recognized for his significant contributions to the life sciences, including his research on excitatory amino acid receptors. Vanda's Board now comprises six members, with the majority being independent directors.
Read more →VNDA▼ -5.4%on this news
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results Q4 2022 total revenues were $64.5 million Full year 2022 revenues were $254.4 million Vanda provides update on pipeline advancements and u
Vanda Pharmaceuticals reported its financial results for Q4 and the full year 2022, showing a total revenue of $254.4 million. Despite a strong overall performance, there was a decline in net product sales for HETLIOZ driven by reimbursement challenges. The company is pursuing regulatory approvals for various treatments, including tradipitant for gastroparesis and Fanapt for bipolar I disorder, both of which are expected to submit NDAs in 2023. However, uncertainties surrounding HETLIOZ's patent litigation have left Vanda unable to provide financial guidance for 2023.
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
Vanda Pharmaceuticals Inc. plans to release its financial results for the fourth quarter and full year of 2022 on February 8, 2023, after market closure. Following the announcement, the company will hold a conference call to discuss the results and other corporate activities. Investors can participate via a domestic or international dial-in and will be able to access a replay of the call shortly after it concludes.
Read more →VNDAFanapt® Shown to be Effective in Bipolar I Disorder in Phase III Clinical Study
Supplemental New Drug Application (sNDA) planned for 2023 WASHINGTON, Dec. 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported positive results in a Phase III clinical study of Fanapt® (iloperidone tablets), a novel atypical antipsychotic, i
Read more →VNDAVanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch WASHINGTON
Vanda Pharmaceuticals Provides an Update to HETLIOZ ANDA Litigation Appeal: Federal Circuit grants motion to temporarily enjoin generic launch WASHINGTON, December 16, 2022 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its appeal of
Read more →VNDA▼ -31.1%on this newsshared move
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ ANDA Litigation WASHINGTON
Vanda Pharmaceuticals Responds to Ruling in HETLIOZ ANDA WASHINGTON, December 13, 2022 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today responded to the ruling in its HETLIOZ ANDA Litigation. Vanda has brought several Hatch-Waxman lawsuits in the United St
Read more →VNDAVanda Pharmaceuticals Reports Results in a Phase II Clinical Study of VQW-765 in the Treatment of Acute Performance Anxiety
WASHINGTON, Dec. 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported results in a Phase II clinical study of VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist, in the treatment of acute perform
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
WASHINGTON, Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2022: The Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022. A co
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2022 Financial Results Q3 2022 total revenues were $65.3 million Total revenues in the first nine months of 2022 were $189.9 million Vanda provides update on pipeline advanceme
Vanda Pharmaceuticals Reports Third Quarter 2022 Financial Results Q3 2022 total revenues were $65.3 million Total revenues in the first nine months of 2022 were $189.9 million Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON - November 2, 202
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2022 Financial Results on November 2, 2022
Conference Call and Webcast to Follow WASHINGTON, Oct. 26, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2022 on Wednesday, November 2, 2022, after the market closes. Vanda will host a confer
Read more →VNDAVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VPO-227, a Novel Candidate for the Treatment of Cholera
WASHINGTON, Oct. 21, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for VPO-227 for the treatment of cholera. While the incidence of cholera in the U.S. is low
Read more →VNDAVanda Pharmaceuticals and OliPass Announce Strategic Partnership to Develop Antisense Oligonucleotide Therapeutics
WASHINGTON, Sept. 29, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and OliPass Corporation (OliPass) (KOSDAQ: 24460) today announced that they have entered into a research and development collaboration agreement to jointly develop a set of antisense olig
Read more →VNDAVANDA PHARMACEUTICALS ANNOUNCES NOTICE OF OPPORTUNITY FOR AN FDA HEARING ON THE sNDA FOR HETLIOZ® IN JET LAG DISORDER
WASHINGTON, Sept. 7, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the notice of opportunity for an FDA hearing on Vanda's Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) to treat jet lag disorder. On August 19, 2019,
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2022 Financial Results Q2 2022 total revenues were $64.4 million Total revenues in the first six months of 2022 were $124.6 million Vanda provides update on pipeline advanceme
Vanda Pharmaceuticals Reports Second Quarter 2022 Financial Results Q2 2022 total revenues were $64.4 million Total revenues in the first six months of 2022 were $124.6 million Vanda provides update on pipeline advancements and upcoming milestones WASHINGTON - August 3, 2022
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2022 Financial Results on August 3, 2022
Conference Call and Webcast to Follow WASHINGTON, July 27, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2022 on Wednesday, August 3, 2022, after the market closes. Vanda will host a confere
Read more →VNDAVanda Pharmaceuticals Announces Participation in the Jefferies 2022 Global Healthcare Conference
WASHINGTON, June 2, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2022 Global Healthcare Conference in New York City on Thursday, June 9, 2022. A corporate presentation is scheduled for 3:
Read more →VNDAVanda Pharmaceuticals Announces Presentations at SLEEP 2022
WASHINGTON, May 31, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2022, to be held in Charlotte, North Carolina from June 4-8, 2022. The following scientific posters will be presented: Presenter: Dr. Sandra Paulina
Read more →VNDAVanda Pharmaceuticals Announces Presentations at DDW 2022
WASHINGTON, May 19, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at Digestive Disease Week (DDW) 2022, to be held in San Diego, CA and online from May 21-24, 2022. The following will be presented: Presentation Title: "THE
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2022 Financial Results WASHINGTON
Vanda Pharmaceuticals Reports First Quarter 2022 Financial Results WASHINGTON - May 5, 2022 PRNewswire - Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq VNDA) today announced financial and operational results for the first quarter ended March 31, 2022. "We are excited with our progr
Read more →VNDAVanda Pharmaceuticals Announces Participation in the BofA Securities 2022 Healthcare Conference
WASHINGTON, May 4, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the BofA Securities 2022 Healthcare Conference in Las Vegas, Nevada on Tuesday, May 10, 2022. A corporate presentation is scheduled for 4
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2022 Financial Results on May 5, 2022
Conference Call and Webcast to Follow WASHINGTON, April 28, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2022 on Thursday, May 5, 2022, after the market closes. Vanda will host a conference
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Full year 2021 total revenues grew to $268.7 million, an 8% increase compared to 2020 Full year 2022 total revenues expected to be between
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results Full year 2021 total revenues grew to $268.7 million, an 8% increase compared to 2020 Full year 2022 total revenues expected to be between $240 million and $280 million End of year 2022 Cash expe
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022
WASHINGTON, Feb. 17, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2021 on Wednesday, February 23, 2022, after the market closes. Vanda will host a conference call at 4:30 PM ET
Read more →VNDA▼ -17.9%on this news
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis
Vanda Pharmaceuticals Reports Results from the Phase III Study of Tradipitant in Gastroparesis WASHINGTON, February 4, 2022 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from its Phase III clinical study, VP-VLY-686-3303, evaluating the
Read more →VNDAVanda Pharmaceuticals Settles HETLIOZ Patent Litigation with
Vanda Pharmaceuticals Settles HETLIOZ Patent Litigation with WASHINGTON, January 14, 2022 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it has entered into a License Agreement (the License Agreement) with MSN Pharmaceuticals Inc., MSN Laboratori
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2021 Investor Conferences
WASHINGTON, Nov. 10, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda management will participate at the following upcoming investor conferences in November 2021: The Stifel 2021 Virtual Healthcare Conference on Monday, November 1
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2021 Financial Results Q3 2021 total revenues were $70.1 million, a 16% increase compared to Q3 2020 Total revenues for the first nine months of 2021 were $200.7 million, an 11
Vanda Pharmaceuticals Reports Third Quarter 2021 Financial Results Q3 2021 total revenues were $70.1 million, a 16% increase compared to Q3 2020 Total revenues for the first nine months of 2021 were $200.7 million, an 11% increase compared to the first nine months of 2020 Enro
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2021 Financial Results on November 3, 2021
WASHINGTON, Oct. 27, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2021 on Wednesday, November 3, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, N
Read more →VNDAVanda Pharmaceuticals Announces Participation at Evercore ISI
WASHINGTON, Oct. 14, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at Evercore ISI's Catalyst Day on Monday, October 18, 2021. Mihael H. Polymeropoulos, M.D., Vanda's President, CEO and Chairman of the Board, will
Read more →VNDAVanda Pharmaceuticals Announces Participation at the Citi 16th Annual BioPharma Virtual Conference
WASHINGTON, Sept. 7, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the Citi 16th Annual BioPharma Virtual Conference taking place between September 8 and September 10, 2021. Vanda management will
Read more →VNDAVanda Pharmaceuticals Closes Enrollment In The ODYSSEY Study Comparing Tradipitant And Placebo In Hospitalized COVID-19 Pneumonia Patients
WASHINGTON, Aug. 3, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that enrollment has closed in the ODYSSEY study comparing tradipitant and placebo in hospitalized COVID-19 pneumonia patients. Enrollment was closed because the study met t
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2021 Financial Results Q2 2021 total revenues were $67.9 million, a 9% increase compared to Q2 2020 Total revenues for the first six months of 2021 were $130.6 million, a 9% i
Vanda Pharmaceuticals Reports Second Quarter 2021 Financial Results Q2 2021 total revenues were $67.9 million, a 9% increase compared to Q2 2020 Total revenues for the first six months of 2021 were $130.6 million, a 9% increase compared to the first six months of 2020 Results
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2021 Financial Results on July 28, 2021
WASHINGTON, July 21, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2021 on Wednesday, July 28, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, Jul
Read more →VNDAVanda Pharmaceuticals Announces Participation at Upcoming 2021 Investor Conferences
WASHINGTON, May 12, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Vanda's management will participate at the following investor conferences: Bank of America Securities 2021 Virtual Health Care Conference on Thursday, May 13, 2021 at
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2021 Financial Results Q1 2021 total revenues were $62.7 million, an 8% increase compared to Q1 2020 The Phase III clinical study of tradipitant in gastroparesis is expected to
Vanda Pharmaceuticals Reports First Quarter 2021 Financial Results Q1 2021 total revenues were $62.7 million, an 8% increase compared to Q1 2020 The Phase III clinical study of tradipitant in gastroparesis is expected to complete enrollment in the second quarter of 2021 A Phas
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2021 Financial Results on May 5, 2021
WASHINGTON, April 20, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2021 on Wednesday, May 5, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 5
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Q4 2020 total revenues grew to $67.7 million, an 11% increase compared to Q4 2019 Full year 2020 total revenues grew to $248.2 million, a
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results Q4 2020 total revenues grew to $67.7 million, an 11% increase compared to Q4 2019 Full year 2020 total revenues grew to $248.2 million, a 9% increase compared to 2019 Full year 2021 total revenu
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results on February 10, 2021
WASHINGTON, Feb. 2, 2021 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2020 on Wednesday, February 10, 2021, after the market closes. Vanda will host a conference call at 4:30 PM ET
Read more →VNDAFDA Approves HETLIOZ (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome WASHINGTON
FDA Approves HETLIOZ (tasimelteon) for the Treatment of Nighttime Sleep Disturbances in Smith-Magenis Syndrome WASHINGTON, December 1, 2020 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has appro
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2020 Financial Results Q3 2020 Total net product sales of $60.3 million, a 1% increase compared to Q3 2019 Total net product sales for the first nine months of 2020 grew to $18
Vanda Pharmaceuticals Reports Third Quarter 2020 Financial Results Q3 2020 Total net product sales of $60.3 million, a 1% increase compared to Q3 2019 Total net product sales for the first nine months of 2020 grew to $180.5 million, a 9% increase compared to the same period in
Read more →VNDAVanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VSJ-110 for Allergic Conjunctivitis
WASHINGTON, Oct. 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to evaluate Cystic Fibrosis Transmembrane Conductance Regulator
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2020 Financial Results on October 28, 2020
WASHINGTON, Oct. 21, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2020 on Wednesday, October 28, 2020, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, O
Read more →VNDAVanda Pharmaceuticals Provides Update on Tradipitant Development Program
WASHINGTON, Aug. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant. Enrollment in Vanda's Phase III clinical study (VP-VLY-686-3303) in gastroparesis is expected to be completed in the f
Read more →VNDAVanda Pharmaceuticals Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia WASHINGTON
Vanda Pharmaceuticals Interim Analysis from ODYSSEY Study Shows Tradipitant may Accelerate Clinical Improvement in Patients with COVID-19 Pneumonia WASHINGTON, August 18, 2020 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today reported that interim analysis s
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2020 Financial Results Q2 2020 Total net product sales reached a new record of $62.2 million, a 7% increase as compared to Q1 2020 Q2 2020 HETLIOZ net product sales reached a
Vanda Pharmaceuticals Reports Second Quarter 2020 Financial Results Q2 2020 Total net product sales reached a new record of $62.2 million, a 7% increase as compared to Q1 2020 Q2 2020 HETLIOZ net product sales reached a new record of $41.6 million, an 18% increase as compared t
Read more →VNDAFDA Accepts and Grants Priority Review of Vanda
WASHINGTON, Aug. 3, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda's applications for Smith-Magenis Syndrome (SMS). The applications include a Supplemen
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2020 Financial Results on August 5, 2020
WASHINGTON, July 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2020 on Wednesday, August 5, 2020, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, Au
Read more →VNDAFDA grants authorization for Individual Patient Expanded Access Protocol for the use of tradipitant for gastroparesis
WASHINGTON, July 13, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that the U.S. Food and Drug Administration (FDA) has authorized a single patient in an Individual Patient Expanded Access protocol (VP-VLY-686-3303). This patient had previ
Read more →VNDAVanda Pharmaceuticals Announces Virtual 2020 Stockholder Meeting
WASHINGTON, May 26, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA), announced today that Vanda will hold its 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") in a virtual-only format due to public health concerns related to the COVID-19 pa
Read more →VNDAVanda Pharmaceuticals CEO
WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today released a letter (below) from Mihael H. Polymeropoulos, M.D., President and CEO of Vanda Pharmaceuticals, proposing an approach to Clinical Trial Data Sharing in order to facilitate
Read more →VNDAVanda Pharmaceuticals Wins Motion To Dismiss False Claims Act Lawsuit
WASHINGTON, May 20, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the Federal District Court in Washington D.C. granted Vanda's motion to dismiss a False Claims Act lawsuit filed against the company. On May 19, 2020, Judge Amit P. Me
Read more →VNDAVanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ for the Treatment of Patients with Smith-Magenis Syndrome WASHINGTON
Vanda Pharmaceuticals Announces Agreement with FDA on Resubmission of the Application for HETLIOZ for the Treatment of Patients with Smith-Magenis Syndrome WASHINGTON, May 13, 2020 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that following the
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2020 Financial Results Q1 2020 Total net product sales of $58.0 million, a 22% increase year over year Advancing the Commercial and Development Pipeline; Initiating Studies for
Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results WASHINGTON May 6, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2020. Our strong financial performance in the fi
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 6, 2020
WASHINGTON, April 29, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2020 on Wednesday, May 6, 2020, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 6
Read more →VNDAVanda Pharmaceuticals Announces Initiation of "CALYPSO" to Study the Role of Genetic Variation in COVID-19 Infections in Collaboration With University of Washington Medicine
WASHINGTON, April 15, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the initiation of the CALYPSO program to study the role that human genetic variations play in SARS-CoV-2 ("COVID-19") infection and disease progression. As a part of the C
Read more →VNDAVanda Pharmaceuticals, Northwell Health Conduct ODYSSEY Trial In Patients With Severe COVID-19 Pneumonia
WASHINGTON, April 15, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and Northwell Health's research arm, The Feinstein Institutes for Medical Research, today announced enrollment of the first patient in Vanda's clinical trial, ODYSSEY VLY-686-3501 (NCT043
Read more →VNDAVanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against COVID-19
WASHINGTON, April 8, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) and the University of Illinois at Chicago (UIC) today announced a research partnership focused on the investigation of small molecules with the potential to treat COVID-19. The collabora
Read more →VNDAVanda Pharmaceuticals Announces the Initiation of ODYSSEY, an FDA Approved Clinical Study of Tradipitant in Hospitalized Patients with Severe COVID-19 Pneumonia
WASHINGTON, April 2, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda") (Nasdaq: VNDA) today announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tr
Read more →VNDAVanda Pharmaceuticals Announces Participation at March 2020 Investor Conferences
WASHINGTON, Feb. 27, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will participate at the following upcoming investor conferences in March 2020: The Cowen and Company 40th Annual Health Care Conference in Boston on Tuesday, Marc
Read more →VNDAVanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis Tradipitant antipruritic effects not seen in moderate or severe Atopic Dermatitis and the study did not meet it
Vanda Reports results from the EPIONE study of Tradipitant in the treatment of Pruritus in Atopic Dermatitis WASHINGTON, Feb. 25, 2020 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced results from a Phase III clinical trial (EPIONE) of tradipitant f
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results Full year 2019 total revenues grew to $227.2 million, an 18% increase compared to 2018 Full year 2020 total revenues expected to be betwee
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results WASHINGTON February 25, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2019. We h
Read more →VNDAVanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors WASHINGTON
Vanda Pharmaceuticals Appoints Stephen Ray Mitchell to Board of Directors WASHINGTON, February 19, 2020 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announces the appointment of Stephen Ray Mitchell, M.D. to its Board of Directors. Ray is a highly respected l
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 25, 2020
WASHINGTON, Feb. 18, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2019 on Tuesday, February 25, 2020, after the market closes. Vanda will host a conference call at 4:30 PM ET o
Read more →VNDAVanda Pharmaceuticals Comments on Court Ruling
WASHINGTON, Jan. 31, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S. District Court for the District of Columbia r
Read more →VNDAVanda Pharmaceuticals Comments on Court Ruling WASHINGTON
Vanda Pharmaceuticals Comments on Court Ruling WASHINGTON Jan. 31, 2020 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) makes the following statement regarding U.S. District Court case 19-cv-30; U.S. Food and Drug Administration (FDA) v. Vanda, in which the U.S.
Read more →VNDAVanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on Fanapt WASHINGTON
Vanda Pharmaceuticals Wins Key U.S. Supreme Court Patent Ruling on WASHINGTON January 13, 2020 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Supreme Court has denied the petition for a writ of certiorari filed by West-Ward Pharmaceuticals (West
Read more →VNDAMihael H. Polymeropoulos, MD, President and CEO of Vanda Pharmaceuticals Inc., to Receive The Physicians Committee for Responsible Medicine Trailblazer Award
WASHINGTON, Dec. 12, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that The Physicians Committee for Responsible Medicine, a nonprofit with more than 12,000 doctor members, will present its inaugural Trailblazer Award to Mihael H. Polymero
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2019 Investor Conferences
WASHINGTON, Nov. 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2019: The Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2019 Financial Results Q3 2019 Total net product sales of $59.5 million, a 21% increase year over year Vanda reiterates full year 2019 revenue guidance of $215 to $225 million
Vanda Pharmaceuticals Reports Third Quarter 2019 Financial Results WASHINGTON November 6, 2019 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2019. These results affirm Vanda s corp
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2019 Financial Results on November 6, 2019
WASHINGTON, Oct. 30, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2019 and provide a general business overview, on Wednesday, November 6, 2019, after the market closes. Vanda will host a conf
Read more →VNDAVanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors WASHINGTON
Vanda Pharmaceuticals Appoints Anne Sempowski Ward to Board of Directors WASHINGTON, October 28, 2019 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that Anne Sempowski Ward has joined the company s Board of Directors, effective October 28, 2019.
Read more →VNDAVanda Announces New Study Results Showing a High Degree of Inbreeding in Beagle Dogs
WASHINGTON, Oct. 23, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced results of a comparative genomics study presented at the 2019 American Society of Human Genetics (ASHG) conference on October 19, 2019, entitled "Using Patterns in Regions
Read more →VNDAVanda Applauds White House Issuance of Executive Orders Requiring Federal Agencies to be Transparent in Policymaking and Enforcement
WASHINGTON, Oct. 16, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, urges fe
Read more →VNDAVanda Pharmaceuticals Applauds the EPA
WASHINGTON, Sept. 11, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, commend
Read more →VNDAVanda Pharmaceuticals Announces the Appointments of a Chief Corporate Affairs and Communications Officer and a Chief Marketing Officer
WASHINGTON, Aug. 21, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients, today an
Read more →VNDAVanda Pharmaceuticals FDA Update for HETLIOZ in the Treatment of Jet Lag Disorder WASHINGTON
Vanda Pharmaceuticals FDA Update for HETLIOZ in the Treatment of Jet Lag Disorder WASHINGTON August 19, 2019 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that on August 16 2019, it received a Complete Response Letter (CRL) from the U.S. Food and Drug Admin
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2019 Financial Results Q2 2019 Total net product sales of $59.1 million, a 25% increase year over year Q2 2019 Hetlioz net product sales grew to $37.8 million, a 35% increase
Vanda Pharmaceuticals Reports Second Quarter 2019 Financial Results WASHINGTON July 31, 2019 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2019. The exceptional commercial performance
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2019 Financial Results on July 31, 2019
WASHINGTON, July 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2019 on Wednesday, July 31, 2019, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, Jul
Read more →VNDATradipitant Effective in Preventing Motion Sickness Washington
Tradipitant Effective in Preventing Motion Sickness Washington, July 16, 2019 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that tradipitant, a neurokinin-1 receptor antagonist, was effective in treating motion sickness in a clinical study conduc
Read more →VNDAVanda Pharmaceuticals to Present at the JMP Securities Life Sciences Conference
WASHINGTON, June 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the JMP Securities Life Sciences Conference in New York City on Wednesday, June 19, 2019 at 2:00 p.m. Eastern Time. The c
Read more →VNDAVanda Pharmaceuticals Announces Participation at the Jefferies 2019 Global Healthcare Conference
WASHINGTON, May 31, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that Mihael H. Polymeropoulos, co-founder and Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 4, 2
Read more →VNDATradipitant in the Treatment of Gastroparesis: Vanda Presents Clinical Trial Results at DDW 2019
WASHINGTON, May 22, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced the results of the Phase II study of tradipitant in gastroparesis were presented at Digestive Disease Week® (DDW) 2019 in San Diego, CA. For more information on DDW 2019, p
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2019 Financial Results Total net product sales of $47.7 million in the first quarter of 2019, a 9% increase year over year Vanda reiterates 2019 net product sales guidance of $
Vanda Pharmaceuticals Reports First Quarter 2019 Financial Results WASHINGTON May 1, 2019 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2019. During the first quarter, Vanda made signif
Read more →VNDAVanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors WASHINGTON
Vanda Pharmaceuticals Appoints Phaedra Chrousos to Board of Directors WASHINGTON, April 24, 2019 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that Phaedra Chrousos has joined Vanda s Board of Directors, effective April 23, 2019. Following Ms.
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2019 Financial Results on May 1, 2019
WASHINGTON, April 18, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2019 on Wednesday, May 1, 2019, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 1
Read more →VNDAVanda Pharmaceuticals to Present at the Cowen and Company 39th Annual Health Care Conference
WASHINGTON, March 7, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Cowen and Company 39th Annual Health Care Conference in Boston, Massachusetts on Monday, March 11, 2019 at 1:30 p.m. E
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results Full year 2018 total revenues grew to $193.1 million, a 17% increase compared to 2017 Full year 2019 total revenues expected to be be
Vanda Pharmaceuticals Reports Fourth Quarter 2018 and Full Year 2018 Financial Results WASHINGTON February 13, 2019 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the fourth quarter and full year ended December 31, 2018.
Read more →VNDAVanda Pharmaceuticals Takes a Stand Against Unnecessary Animal Research Company pursuing legal action against the FDA for requiring unnecessary studies that would result in the death of dozens of dogs without legal autho
Vanda Pharmaceuticals Takes a Stand Against Unnecessary Animal Research Company pursuing legal action against the FDA for requiring unnecessary studies that would result in the death of dozens of dogs without Washington, DC February 5, 2019 Vanda Pharmaceuticals Inc. has filed
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019
WASHINGTON, Jan. 25, 2019 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2018 on Wednesday, February 13, 2019, after the market closes. Vanda will host a conference call at 4:30 PM ET
Read more →VNDAFDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application for Review in the Treatment of Jet Lag Disorder
WASHINGTON, Dec. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of Vanda's Supplemental New Drug Application for HETLIOZ® (tasimelteon) for the treatment of jet la
Read more →VNDAVanda Announces Positive Pivotal Study Results for HETLIOZ (tasimelteon) in Patients with Smith-Magenis Syndrome WASHINGTON
Vanda Announces Positive Pivotal Study Results for HETLIOZ (tasimelteon) in Patients with Smith-Magenis Syndrome WASHINGTON, December 10, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that HETLIOZ (tasimelteon) improved sleep quality and i
Read more →VNDAVanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis Management to host conference call on Monday, December 3 at 8:30 AM ET Washington
Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis Management to host conference call on Monday, December 3 at 8:30 AM ET Washington, December 3, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq:VNDA) today announced that
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2018 Investor Conferences
WASHINGTON, Nov. 8, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2018: The Stifel 2018 Healthcare Conference in New York City on Tuesday, November 13, 20
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2018 Financial Results Hetlioz net product sales grew to $29.9 million in the third quarter of 2018, a 34% increase compared to the third quarter of 2017 Results from clinical
Vanda Pharmaceuticals Reports Third Quarter 2018 Financial Results WASHINGTON November 7, 2018 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2018. HETLIOZ (tasimelteon) Fanapt (ilo
Read more →VNDAVanda Receives FDA Letter Regarding Corporate Webpage
WASHINGTON, Nov. 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it received a letter from the U.S. Food and Drug Administration (FDA) Office of Prescription Drug Promotion on October 22, 2018 regarding the content on a single page o
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2018 Financial Results on November 7, 2018
WASHINGTON, Oct. 22, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter of 2018 on Wednesday, November 7, 2018, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday
Read more →VNDAVanda Pharmaceuticals Announces Participation at Oppenheimer and Cantor Fitzgerald Fall 2018 Investor Conferences
WASHINGTON, Sept. 26, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming 2018 investor conferences: The Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease in New York City on T
Read more →VNDAVanda Announces Listing of a New HETLIOZ® Patent in the FDA Orange Book
WASHINGTON, Sept. 20, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that a HETLIOZ® patent, number 10,071,977 ('977 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equival
Read more →VNDAHETLIOZ® (Tasimelteon) Driving Study Demonstrates No Impairment in Next Morning Performance
WASHINGTON, Sept. 12, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the results of a HETLIOZ® (tasimelteon) driving study to measure next day performance. Tasimelteon did not impair measures of driving performance, whereas the active contr
Read more →VNDAVanda Pharmaceuticals Announces Participation at September 2018 Investor Conferences
WASHINGTON, Sept. 4, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2018: The Citigroup 13th Annual Biotech Conference in Boston on Wednesday, September 5
Read more →VNDAVanda Wins Denial of Petition For Rehearing on Fanapt U.S. Court of Appeals Denies Petitions for Panel Rehearing and Rehearing En Banc WASHINGTON
Vanda Wins Denial of Petition For Rehearing on Fanapt U.S. Court of Appeals Denies Petitions for Panel Rehearing and Rehearing En Banc WASHINGTON, August 14, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for t
Read more →VNDAVanda Pharmaceuticals Announces the Appointment of General Counsel
WASHINGTON, Aug. 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has named Timothy Williams as Vanda's Senior Vice President, General Counsel and Secretary. "I am very pleased to welcome Tim to the Vanda executive management tea
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2018 Financial Results Total net product sales were $47.4 million in the second quarter of 2018 Hetlioz net product sales grew to $28.0 million in the second quarter of 2018 F
Vanda Pharmaceuticals Reports Second Quarter 2018 Financial Results WASHINGTON August 1, 2018 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2018. We are excited with the year to date HE
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2018 Financial Results on August 1, 2018
WASHINGTON, July 17, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2018 on Wednesday, August 1, 2018, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday,
Read more →VNDAVanda Pharmaceuticals Announces Participation at June 2018 Investor Conferences
WASHINGTON, June 1, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2018: The Jefferies 2018 Global Healthcare Conference in New York City on Tuesday, June 5, 2
Read more →VNDAHETLIOZ (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel HETLIOZ demonstrates significant improvement in objective and subjective measures of Jet Lag during 5 hour and 8 hour time zone transatlanti
HETLIOZ (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel WASHINGTON, May 23, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced results from the JET Study (VP-VEC-162-2102), a 3-night transatlantic travel study of the effe
Read more →VNDAVanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
WASHINGTON, May 7, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), today announced that it will deliver a corporate presentation at the Deutsche Bank 43rd Annual Health Care Conference in Boston, Massachusetts on Wednesday, May 9, 2018 at 8:00 a.m. Eastern
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2018 Financial Results Total net product sales were $43.6 million in the first quarter of 2018 Vanda reiterates 2018 net product sales guidance of $180 million to $200 million
Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results WASHINGTON May 2, 2018 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2018. We are pleased with the progress made in 20
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018
WASHINGTON, April 18, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2018 on Wednesday, May 2, 2018, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, Ma
Read more →VNDAVanda Wins Appeal Case on Fanapt U.S. Court of Appeals Affirms District Court s Decision WASHINGTON
Vanda Wins Appeal Case on Fanapt U.S. Court of Appeals Affirms District Court s Decision WASHINGTON, April 13, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District
Read more →VNDAVanda Wins Appeal Case on Fanapt®
WASHINGTON, April 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) announced today that the U.S. Court of Appeals for the Federal Circuit affirmed the U.S. District Court for the District of Delaware's decision that West Ward Pharmaceuticals, a subsidiar
Read more →VNDAVanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
WASHINGTON, April 9, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (Nasdaq: VNDA) today announced participation at the 2018 Georg Rajka International Symposium of Atopic Dermatitis (ISAD 2018) in Utrecht, Netherlands in the scientific poster forum on Thursday, April 12,
Read more →VNDAVanda Pharmaceuticals Inc. Prices Public Offering of Common Stock WASHINGTON
Vanda Pharmaceuticals Inc. Prices Public Offering of Common Stock WASHINGTON, March 15, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the sale of 5,500,000 shares of its common stock in an underwritten public offering at a price to the publ
Read more →VNDAVanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock WASHINGTON
Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock WASHINGTON, March 14, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The off
Read more →VNDAVanda Pharmaceuticals Announces Participation at March 2018 Investor Conferences
WASHINGTON, March 6, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in March 2018. The Cowen and Company 38th Annual Healthcare Conference in Boston on Monday, March 1
Read more →VNDAHETLIOZ (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study H ETLIOZ demonstrates improve ment in Total Sleep Time by 85 minutes versus Placebo (p 0.0001) H ETLIOZ demo
HETLIOZ (tasimelteon) Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study conference call today at 8:30 AM ET WASHINGTON, March 5, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ , a circad
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results Full year 2017 total revenues grew to $165.1 million, a 13% increase compared to 2016 WASHINGTON
Vanda Pharmaceuticals Reports Fourth Quarter 2017 and Full Year 2017 Financial Results Full year 2017 total revenues grew to $165.1 million, a 13% increase compared to 2016 WASHINGTON February 14, 2018 Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results on February 14, 2018
WASHINGTON, Jan. 30, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter and full year 2017 on Wednesday, February 14, 2018, after the market closes. Vanda will host a conference call at 4:30 PM ET
Read more →VNDAVanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance 2017 Total revenues are expected to be approximately $165 million 2018 Total revenues are expected to be betwe
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance January 7, 2018 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel th
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2017 Investor Conferences
WASHINGTON, Nov. 13, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2017. The Stifel 2017 Healthcare Conference in New York City on Tuesday, November 14, 2
Read more →VNDAVanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum™ for the Treatment of Schizophrenia
WASHINGTON, Nov. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today the refusal of the marketing authorization application (MAA) of Fanaptum™ (oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Un
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2017 Financial Results Total net product sales were $41.3 million in the third quarter of 2017 HETLIOZ to psychiatrists initiative fully launched in October 2017 Tradipitant st
Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results WASHINGTON November 7, 2017 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the third quarter ended September 30, 2017. During the third quarter of 2017,
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2017 Financial Results on November 7, 2017
WASHINGTON, Oct. 24, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2017 on Tuesday, November 7, 2017, after the market closes. Vanda will host a conference call at 4:30 PM ET on Tuesday, No
Read more →VNDAVanda Pharmaceuticals Announces Participation at the Oppenheimer Specialty Pharma Summit Conference
WASHINGTON, Oct. 10, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will host investor meetings at the Oppenheimer Specialty Pharma Summit Conference in New York City on Wednesday, October 11, 2017. About Vanda Pharmaceuticals Inc.
Read more →VNDAVanda to Present Tradipitant Phase II Atopic Dermatitis Data at World Congress of Itch
WASHINGTON, Oct. 2, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the results of the Phase II study of tradipitant in atopic dermatitis will be presented at the 9th World Congress of Itch in Wroclaw Poland as a late breaking
Read more →VNDAVanda to Present Scientific Posters at World Sleep 2017
WASHINGTON, Sept. 29, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced participation at the 2017 joint congress of World Association of Sleep Medicine and World Sleep Federation (World Sleep 2017) in Prague, Czech Republic in the scientific p
Read more →VNDAVanda s Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis Worst Itch Visual Analog Scale (Worst Itch VAS): Tradipitant vs. Placebo p=0.019 Scoring Atopic Dermatitis (SCORAD): Tradipitant v
Vanda s Tradipitant Improves Itch and Disease Severity in Patients with Atopic Dermatitis to host conference call on Thursday, September 14 at 8:30 AM ET WASHINGTON, September 13, 2017 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced results from
Read more →VNDAVanda Pharmaceuticals Announces Participation at September 2017 Investor Conferences
WASHINGTON, Sept. 11, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in September 2017. The Rodman and Renshaw 19th Annual Global Investment Conference in New York Cit
Read more →VNDAVanda Pharmaceuticals Announces Participation at the Citi 12th Annual Biotech Conference
WASHINGTON, Sept. 6, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the Citi 12th Annual Biotech Conference. Vanda will host meetings at the Citi Biotech Conference in Boston on Thursday, September 7, 2017. Abou
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2017 Financial Results Total net product sales were $42.1 million in the second quarter of 2017 Hetlioz net product sales grew to $22.5 million in the second quarter of 2017 F
Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results WASHINGTON August 2, 2017 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the second quarter ended June 30, 2017. During the second quarter of 2017, we a
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2017 Financial Results on August 2, 2017
WASHINGTON, July 17, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2017 on Wednesday, August 2, 2017, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday,
Read more →VNDAVanda Pharmaceuticals Announces Participation at June 2017 Investor Conferences
WASHINGTON, June 5, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in June 2017. The Jefferies 2017 Global Healthcare Conference in New York City on Wednesday, June 7,
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2017 Financial Results Total net product sales were $37.4 million in the first quarter of 2017 Vanda reiterates 2017 net product sales guidance of $165 million to $175 million
Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results WASHINGTON May 2, 2017 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2017. We are pleased with the progress made in t
Read more →VNDAVanda Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
WASHINGTON, May 1, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will deliver a corporate presentation at the Deutsche Bank 42nd Annual Health Care Conference in Boston, Massachusetts on Thursday, May 4, 2017 at 8:40 a.m. Eastern T
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
WASHINGTON, April 13, 2017 /PRNewswire/ -- Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2017 on Tuesday, May 2, 2017, after the market closes. Vanda will host a conferenc
Read more →VNDAVanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors
WASHINGTON, March 29, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has entered into a license agreement with UC San Francisco (UCSF), under which Vanda will acquire an exclusive worldwide license from UCSF to develop and commercia
Read more →VNDAVanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences
WASHINGTON, March 6, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in March 2017. The Cowen and Company 37th Annual Healthcare Conference in Boston on Tuesday, March
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results Full year 2016 total revenues grew to $146 million, a 33% increase compared to 2015 WASHINGTON
Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results WASHINGTON February 15, 2017 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2016.
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017
WASHINGTON, Jan. 19, 2017 /PRNewswire/ -- Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2016 on Wednesday, February 15, 2017, after the market closes. Vanda will host a c
Read more →VNDAVanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance 2016 Total revenues are expected to be approximately $146 million 2017 Total revenues are expected t
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance January 9, 2017 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization o
Read more →VNDAVanda Pharmaceuticals Settles Fanapt Patent Litigation with Apotex Vanda Grants Apotex a license to sell generic Fanapt beginning November 2027 WASHINGTON
Vanda Pharmaceuticals Settles Fanapt Patent Litigation with Apotex Vanda Grants Apotex a license to sell generic Fanapt beginning November 2027 WASHINGTON, December 7, 2016 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it has entered into a License Agreem
Read more →VNDAVanda Pharmaceuticals Announces Participation at November 2016 Investor Conferences
WASHINGTON, Nov. 14, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it will participate at the following upcoming investor conferences in November 2016. The Stifel 2016 Healthcare Conference in New York City on Tuesday, November 15, 2
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2016 Financial Results Total revenues grew to $38.5 million, a 7% increase compared to the second quarter of 2016 and a 36% increase compared to the same period in 2015 WASHING
Vanda Pharmaceuticals Reports Third Quarter 2016 Financial Results WASHINGTON November 2, 2016 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the third quarter ended September 30, 2016. This quarter marks a significant
Read more →VNDAVanda Pharmaceuticals Settles Fanapt Patent Litigation with Taro Vanda Grants Taro a license to sell generic Fanapt beginning November 2027 WASHINGTON
Vanda Pharmaceuticals Settles Fanapt Patent Litigation with Taro Vanda Grants Taro a license to sell generic Fanapt beginning November 2027 WASHINGTON, October 24, 2016 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it has entered into a License Agreement
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2016 Financial Results on November 2, 2016
WASHINGTON, Oct. 12, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2016 on Wednesday, November 2, 2016, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday
Read more →VNDAUSPTO Dismisses Petition for Inter Partes Review of Fanapt® Patent
WASHINGTON, Aug. 30, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the United States Patent and Trademark Office (USPTO) Patent Trials and Appeal Board declined the request by Roxane Laboratories, Inc. (Roxane) to institute an inter p
Read more →VNDAVanda Patents Found Valid and Infringed in Fanapt ANDA Litigation WASHINGTON
Vanda Patents Found Valid and Infringed in Fanapt ANDA Litigation WASHINGTON, August 25, 2016 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Judge Gregory M. Sleet of the United States District Court for the District of Delaware ruled that R
Read more →VNDAHETLIOZ is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany HETLIOZ (tasimelteon) is the first and only product to receive approval for the treatment of Non-24 in the European Union WASHINGTO
HETLIOZ is Now Available for the Treatment of Non-24-Hour Sleep-Wake Disorder in Germany WASHINGTON, August 1, 2016 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that HETLIOZ (tasimelteon) is now available for the treatment of Non-24-Hour Sleep-W
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2016 Financial Results HETLIOZ net product sales grew to $17.5 million in the second quarter 2016 Fanapt net product sales grew to $18.6 million in the second quarter 2016 Van
Vanda Pharmaceuticals Reports Second Quarter 2016 Financial Results WASHINGTON July 27, 2016 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June 30, 2016. Vanda s commercial business continues t
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2016 Financial Results on July 27, 2016
WASHINGTON, July 12, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2016 on Wednesday, July 27, 2016, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday,
Read more →VNDAFDA Grants Fanapt Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia WASHINGTON
FDA Grants Fanapt Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia WASHINGTON, June 15, 2016 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (F
Read more →VNDAVanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference
WASHINGTON, June 3, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced that it will deliver a corporate presentation at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 10:00 a.m. Eastern Time. The presentatio
Read more →VNDAVanda Announces FDA Approval of the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults WASHINGTON
Vanda Announces FDA Approval of the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults WASHINGTON, May 26, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administrati
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2016 Financial Results HETLIOZ net product sales grew to $16.2 million in the first quarter 2016 Fanapt net product sales grew to $17.1 million in the first quarter 2016 Vanda
Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results WASHINGTON May 4, 2016 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31, 2016. Vanda made significant progress in the fir
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016
WASHINGTON, April 14, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the first quarter of 2016 on Wednesday, May 4, 2016, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, Ma
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results HETLIOZ net product sales grew to $15.1 million in the fourth quarter 2015 Full year 2015 total revenues grew to $109.9 million WASHI
Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results WASHINGTON February 10, 2016 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2015
Read more →VNDAVanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day
WASHINGTON, Feb. 1, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of novel therapies addressing high unmet medical needs, today announced that members of its management team wil
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016
WASHINGTON, Jan. 22, 2016 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the fourth quarter of 2015 on Wednesday, February 10, 2016, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesd
Read more →VNDAVanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance Fourth quarter 2015 HETLIOZ net product sales are expected to be approximately $15.1 million 2015 Total reve
Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance WASHINGTON, January 11, 2016 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercializat
Read more →VNDAEuropean Medicines Agency Accepts Fanaptum (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults WASHINGTON
European Medicines Agency Accepts Fanaptum (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults WASHINGTON, December 22, 2015 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that its Marketing Authorizati
Read more →VNDAKenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals WASHINGTON
Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals WASHINGTON, December 18, 2015 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that Kenneth Bate, an independent biotechnology industry consultant, has joined Vanda s Board of Dire
Read more →VNDAVanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial Officer
WASHINGTON, Dec. 17, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has appointed Gian Piero Reverberi to the role of Senior Vice President, Acting Chief Commercial Officer and European General Manager. Mr. Reverberi was previously
Read more →VNDAVanda Pharmaceuticals Announces Participation at Upcoming Investor Conferences
WASHINGTON, Nov. 12, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will participate at
Read more →VNDAVanda Pharmaceuticals to Participate in the Citi 2015 Global Healthcare 1x1 Conference
WASHINGTON, Nov. 4, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Polymeropoulo
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2015 Financial Results Vanda affirms its full year net product sales guidance of between $100 million and $115 million Conference call scheduled for 4:30 p.m. ET today WASHINGT
Vanda Pharmaceuticals Reports Third Quarter 2015 Financial Results Vanda affirms its full year net product sales guidance of between $100 million and $115 million Conference call scheduled for 4:30 p.m. ET today WASHINGTON November 3, 2015 Vanda Pharmaceuticals Inc. (Vanda) (N
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2015 Financial Results on November 3, 2015
WASHINGTON, Oct. 15, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the third quarter of 2015 on Tuesday, November 3, 2015, after the market closes. The Company will host a conference call at 4:30 PM ET on Tuesd
Read more →VNDAVanda Announces Listing of a New Fanapt® Patent in the FDA Orange Book
WASHINGTON, Oct. 14, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a Fanapt® patent, number 9,157,121 ('121 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalenc
Read more →VNDAVanda Announces FDA Has Accepted for Review the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults WASHINGTON
Vanda Announces FDA Has Accepted for Review the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults WASHINGTON, September 15, 2015 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the U.S. Food and Dr
Read more →VNDAVanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation
WASHINGTON, Sept. 10, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that a favorable Markman ruling has been issued by the United States District Court for the District of Delaware in the patent infringement lawsuit filed by Vanda against
Read more →VNDAVanda Pharmaceuticals Announces the Appointment of European General Manager
WASHINGTON, Sept. 8, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Gian Piero Reverberi as Vanda's Senior Vice President, European General Manager. Mr. Reverberi has more than 20 years of experience in the pharmaceutical
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2015 Financial Results HETLIOZ U.S. net product sales increased by 34% over the prior quarter to $10.0 million Fanapt U.S. net product sales increased by 20% over the prior qu
Vanda Pharmaceuticals Reports Second Quarter 2015 Financial Results Conference call scheduled for 4:30 p.m. ET today WASHINGTON July 29, 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the second quarter ended June
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2015 Financial Results on July 29, 2015
WASHINGTON, July 9, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2015 on Wednesday, July 29, 2015, after the market closes. The Company will host a conference call at 4:30 PM ET on Wednes
Read more →VNDAHETLIOZ Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind - HETLIOZ , a circadian regulator, is the first and only product to receive approval for Non-24 in t
HETLIOZ Receives European Commission Approval for the Treatment of Non-24-Hour Sleep-Wake Disorder in the Totally Blind - HETLIOZ , a circadian regulator, is the first and only product to receive approval for Non-24 in the European Union WASHINGTON, July 7, 2015 /PRNewswire/
Read more →VNDAVanda Announces Positive Results from the Relapse Prevention Study in Patients with Schizophrenia (REPRIEVE) Demonstrating the Long-Term Maintenance Effects of Fanapt® (iloperidone)
WASHINGTON, June 23, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today presented positive results from the long-term maintenance REPRIEVE (Relapse prevention study in patients with schizophrenia) clinical study at the 2015 American Society of Clinical
Read more →VNDAVanda Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference
WASHINGTON, June 2, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Polymeropoulo
Read more →VNDAVanda Receives Innovation Award from the National Organization for Rare Disorders for Development of HETLIOZ®
WASHINGTON, May 26, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has received the 2015 Industry Innovation Award from the National Organization of Rare Disorders (NORD) in recognition of Vanda's work in developing HETLIOZ® (tasime
Read more →VNDAVanda Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
WASHINGTON, May 11, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Polymeropoulo
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2015 Financial Results HETLIOZ net product sales increased by 24% over the prior quarter to $7.5 million, patients on active treatment grew by 22% over the prior quarter Fanapt
Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results Conference call scheduled for 4:30 p.m. ET today WASHINGTON May 6, 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the first quarter ended March 31,
Read more →VNDAVanda recibe opinión para HETLIOZ® (tasimelteon) para tratar la enfermedad del sueño retrasado non-24-horas
- Vanda recibe la opinión positiva del CHMP para HETLIOZ® (tasimelteon) para el tratamiento de la enfermedad del sueño retrasado non-24-horas en la Unión Europea - HETLIOZ®, un regulador circadiano, es el primer y único producto que recibe recomendación para su aprobación como n
Read more →VNDAVanda obtient un avis favorable du CHMP pour HETLIOZ® (tasimelteon) en vue du traitement du syndrome hyper-nycthéméral au sein de l
- HETLIOZ®, un régulateur circadien, est le premier et le seul produit à recevoir une recommandation d'approbation pour le syndrome hyper-nycthéméral au sein de l'Union européenne - L'Agence européenne des médicaments devrait prendre sa décision finale dans environ deux mois WA
Read more →VNDAVanda erhält positive Stellungnahme des CHMP für HETLIOZ® (Tasimelteon) zur Behandlung der Schlaf-Wach-Störung bei Abweichung vom 24-Stunden-Rhythmus in der Europäischen Union
- HETLIOZ®, ein Arzneimittel zur Synchronisation des 24-Stunden-Rhythmus, ist das erste und einzige Produkt, das in der Europäischen Union eine Zulassungsempfehlung für Non-24 erhält - Europäische Arzneimittelagentur wird endgültige Entscheidung in ca. zwei Monaten bekanntgeben
Read more →VNDAVanda Receives Positive CHMP Opinion for HETLIOZ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union HETLIOZ , a circadian regulator, is the first and only product to receive a recomm
Vanda Receives Positive CHMP Opinion for HETLIOZ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union April 24, 2015/PRNEWSWIRE/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that the European Medicines Agency s (EMA) Comm
Read more →VNDAVanda Pharmaceuticals Announces the Appointment of Chief Commercial Officer
WASHINGTON, April 20, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that it has named Tom Gibbs as Senior Vice President, Chief Commercial Officer of the company. Mr. Gibbs has 20 years of experience in the pharmaceutical industry, includi
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015
WASHINGTON, April 16, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results fo
Read more →VNDAVanda Announces Trial Date for Fanapt® Patent Cases
WASHINGTON, April 13, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced a February 29, 2016 trial date for two pending cases against Roxane Laboratories Inc. regarding Roxane's submission of an Abbreviated New Drug Application (ANDA) to obtain
Read more →VNDAVanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis Tradipitant and placebo both showed significant improvements from baseline No significant effe
Vanda Pharmaceuticals Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatitis WASHINGTON, March 4, 2015 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced top-line results of the Phase II proof of conce
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results HETLIOZ net product sales in the U.S. grew to $6.0 million in the fourth quarter of 2014, a 15% increase as compared to the third qua
Vanda Pharmaceuticals Reports Fourth Quarter 2014 and Full Year 2014 Financial Results WASHINGTON February 19, 2015 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the fourth quarter and full year ended December 31, 2014.
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter 2014 Financial Results on February 19, 2015
WASHINGTON, Feb. 2, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda to regain US and Canadian rights to Fanapt - Vanda and Novartis Agree to Settle Arbitration - Novartis to purchase $25 million of Vanda common stock - Vanda to acquire rights to a Phase II clinical compound from No
Vanda to regain US and Canadian rights to Fanapt - Vanda and Novartis Agree to Settle Arbitration Novartis to purchase $25 million of Vanda common stock - Vanda to acquire rights to a Phase II clinical compound from Novartis WASHINGTON, December 22, 2014 /PRNewswire/ Vanda Ph
Read more →VNDAVanda Pharmaceuticals to Present at the 26th Annual Piper Jaffray Healthcare Conference
WASHINGTON, Dec. 1, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corpo
Read more →VNDAVanda Pharmaceuticals to Present at the Stifel Nicolaus 2014 Healthcare Conference
WASHINGTON, Nov. 18, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corp
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2014 Financial Results HETLIOZ U.S. sales grew to $5.2 million in the first full quarter since launch HETLIOZAccess Named Patient Program launched in Europe and Canada Fanapt g
Vanda Pharmaceuticals Reports Third Quarter 2014 Financial Results WASHINGTON October 27, 2014 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), today announced financial and operational results for the third quarter ended September 30, 2014. Our innovative approach to the co
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2014 Financial Results on October 27, 2014
WASHINGTON, Oct. 14, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2014 Results WASHINGTON
Vanda Pharmaceuticals Reports Second Quarter 2014 Results WASHINGTON August 7, 2014 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders,
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2014 Financial Results on August 7, 2014
WASHINGTON, July 17, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda Pharmaceuticals Inc. 2014 Corporate Presentation Forward Looking Statements 2 All written and verbal forward looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in th
Caution should be exercised when HETLIOZ is administered to a nursing woman. HETLIOZ has not been studied in patients with severe hepatic impairment and is not recommended in these patients. Safety and effectiveness of HETLIOZ in pediatric patients have not been established. Full
Read more →VNDAEuropean Medicines Agency Accepts HETLIOZ TM (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind WASHINGTON
European Medicines Agency Accepts HETLIOZTM (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind WASHINGTON, June 3, 2014/PRNEWSWIRE/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Auth
Read more →VNDAEuropean Medicines Agency Accepts HETLIOZ™ (tasimelteon) Marketing Authorization Application for Non-24-Hour Sleep-Wake Disorder in the Totally Blind
WASHINGTON, June 3, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that its Marketing Authorization Application (MAA) for oral HETLIOZ™ (tasimelteon) capsules has been accepted for evaluation by the European Medicines Agency (EMA) for the t
Read more →VNDAHETLIOZ™ (tasimelteon) Data in Patients with Non-24-Hour Sleep-Wake Disorder to be presented at SLEEP 2014 meeting
WASHINGTON, June 2, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) will present additional data from its HETLIOZ™ (tasimelteon) clinical development program at SLEEP 2014, the 28th Annual Meeting of Associated Professional Sleep Societies in Minneapolis, M
Read more →VNDAVanda Pharmaceuticals to Present at the Jefferies 2014 Global Healthcare Conference
WASHINGTON, May 29, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corpo
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2014 Results WASHINGTON
Vanda Pharmaceuticals Reports First Quarter 2014 Results WASHINGTON May 8, 2014 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, tod
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2014 Financial Results on May 8, 2014
WASHINGTON, April 24, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results fo
Read more →VNDAVanda Pharmaceuticals Announces Availability of HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24) Vanda launches HETLIOZ Solutions , a patient resource for information and access to
Vanda Pharmaceuticals Announces Availability of HETLIOZ (tasimelteon) for Non-24-Hour Sleep-Wake Disorder (Non-24) Vanda launches HETLIOZSolutions , a patient resource for information and access April 9, 2014 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today
Read more →VNDABlind Adventurer, Erik Weihenmayer, Launches National Campaign to Raise Awareness of Non-24-Hour Sleep-Wake Disorder
WASHINGTON, Feb. 28, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that it has partnered with Erik Weihenmayer, a world-renowned adventurer and the only blind person to climb Mount Everest, to support the Non-24 Share More Campaign and lau
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results WASHINGTON
Vanda Pharmaceuticals Reports Fourth Quarter 2013 and Full Year 2013 Results WASHINGTON February 13, 2014 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central ner
Read more →VNDAFDA Approves HETLIOZ™ (tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder
WASHINGTON, Jan. 31, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has approved HETLIOZ™ (tasimelteon) 20mg capsules for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24). HETLIOZ™ i
Read more →VNDAFDA APPROVES HETLIOZ TM (TASIMELTEON) FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER Non-24 is highly prevalent among the totally blind WASHINGTON
FDA APPROVES HETLIOZTM (TASIMELTEON) FOR THE TREATMENT OF NON-24-HOUR SLEEP-WAKE DISORDER Non-24 is highly prevalent among the totally blind WASHINGTON, January 31, 2014 /PRNewswire/ Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter 2013 Financial Results on February 13, 2014
WASHINGTON, Jan. 23, 2014 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
WASHINGTON, Dec. 3, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corpo
Read more →VNDAFDA Advisory Committee Recommends Approval of HETLIOZ for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind HETLIOZ is the First Potential Treatment to be Reviewed by the FDA for Non-24 WASHINGTON
FDA Advisory Committee Recommends Approval of HETLIOZ for the Treatment of Non-24-Hour-Disorder (Non-24) in the Totally Blind HETLIOZ is the First Potential Treatment to be Reviewed by the FDA for Non-24 WASHINGTON, November 14, 2013 Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ:
Read more →VNDAVanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ™ NDA
WASHINGTON, Nov. 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that NASDAQ halted trading
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2013 Results WASHINGTON
Vanda Pharmaceuticals Reports Third Quarter 2013 Results WASHINGTON November 7, 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2013 Financial Results on November 7, 2013
WASHINGTON, Oct. 21, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda Pharmaceuticals Announces FDA Advisory Committee Meeting On November 14, 2013
WASHINGTON, Oct. 16, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has notified the company of the scheduling of a Peripheral and Central Nervous System Drugs Advisory Committee meeting on N
Read more →VNDAVanda Pharmaceuticals to Present at the Stifel Nicolaus 2013 Healthcare Conference
WASHINGTON, Sept. 10, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a cor
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2013 Results WASHINGTON
Vanda Pharmaceuticals Reports Second Quarter 2013 Results WASHINGTON July 31, 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders,
Read more →VNDAFDA ACCEPTS TASIMELTEON NEW DRUG APPLICATION FOR PRIORITY REVIEW IN THE TREATMENT OF NON-24-HOUR
FDA ACCEPTS TASIMELTEON NEW DRUG APPLICATION FOR PRIORITY REVIEW IN THE TREATMENT OF NON-24-HOUR DISORDER IN THE TOTALLY BLIND WASHINGTON, July 29, 2013 Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepte
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2013 Financial Results on July 31, 2013
WASHINGTON, July 29, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda Pharmaceuticals to Participate in Upcoming Investor Conferences
WASHINGTON, July 8, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will participate in
Read more →VNDAVanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder
WASHINGTON, June 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional data today at ENDO 2013, the Endocrine Society's 95th Annual Meeting, demonstrating that tasimelteon can entrain (synchronize) both melatonin and cortisol rhythms. Thi
Read more →VNDAVanda Presents Data From Tasimelteon Phase III Studies In Non-24-Hour Disorder
WASHINGTON, June 5, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) presented additional entrainment and patient-level clinical data at SLEEP 2013, the 27th Annual Meeting of Associated Professional Sleep Societies in Baltimore, from its SET (Safety and Eff
Read more →VNDAVanda Announces Submission To FDA Of A New Drug Application For Tasimelteon For The Treatment Of Non-24-Hour Disorder In The Totally Blind
WASHINGTON, May 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tasimelteon, a circadian regulator. Vanda is seeking FDA approval of tasime
Read more →VNDAVanda Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare Conference
WASHINGTON, May 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliver a corpo
Read more →VNDAVanda to Present Tasimelteon Non-24 Phase III Data at Two Medical Meetings
WASHINGTON, May 30, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (VANDA) (NASDAQ: VNDA) today announced that data from the Phase III studies of tasimelteon in Non-24-Hour Disorder (Non-24) will be presented at SLEEP 2013, the 27th Annual Meeting of the Associated Professional
Read more →VNDAVanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland
WASHINGTON, May 23, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company has been named the 2013 Life Science Firm of the Year by the Tech Council of Maryland (TCM). Vanda was honored at the TCM's 25th Annual Tech Awards Celebrati
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2013 Results WASHINGTON
Vanda Pharmaceuticals Reports First Quarter 2013 Results WASHINGTON May 9, 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, tod
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2013 Financial Results on May 9, 2013
WASHINGTON, April 18, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results fo
Read more →VNDAVanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi, M.D., Ph.D. as its Senior Vice President and Chief Medical Officer. Dr. Baroldi has over 30 years of clinical development experience in
Read more →VNDAVanda Pharmaceuticals to Present at the BioCentury Future Leaders in the Biotech Industry Conference
WASHINGTON, April 4, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Jim Kelly, Vanda's Chief Financial Officer, will deliver a corporate presentation at the BioCentury Future Leaders in the Biotech Industry Conference in New York on Fr
Read more →VNDAVANDA REPORTS SUCCESSFUL COMPLETION OF PRE-NDA MEETING WITH FDA ON TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR
VANDA REPORTS SUCCESSFUL COMPLETION OF PRE-NDA MEETING WITH FDA ON TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR DISORDER IN THE TOTALLY BLIND WASHINGTON, March 25, 2013 /PRNewswire/ Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the company held a pre-NDA
Read more →VNDAVanda Withdraws Its Marketing Authorization Application For Fanaptum™ In The European Union
WASHINGTON, March 14, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced today that it has withdrawn its Marketing Authorization Application (MAA) submitted to the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for
Read more →VNDAVanda Pharmaceuticals to Present at the Cowen and Company 33rd Annual Health Care Conference
WASHINGTON, Feb. 27, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced that Mihael Polymeropoulos, M.D., Vanda's President and CEO, will deliver a corporate presentation at the Cowen and Company 33rd Annual Health Care Conference in Boston on
Read more →VNDACristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (202) 734-3414 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results WASHIN
Senior Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results WASHINGTON February 12, 2013 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company fo
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
WASHINGTON, Feb. 12, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational r
Read more →VNDAVANDA ANNOUNCES PHASE IIB/III
VANDA ANNOUNCES PHASE IIB/III CLINICAL STUDY IN MAJOR DEPRESSIVE DISORDER DID NOT MEET THE PRIMARY ENDPOINT WASHINGTON, January 31, 2013 /PRNewswire/ Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major
Read more →VNDAVanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint
WASHINGTON, Jan. 31, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) today announced top-line results of the Phase IIb/III clinical study (MAGELLAN) in Major Depressive Disorder (MDD), investigating the efficacy and safety of tasimelteon as a monotherapy in the tre
Read more →VNDAVANDA ANNOUNCES POSITIVE RESULTS IN THE SECOND PHASE III STUDY (RESET) OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR DISORDER Tasimelteon significantly maintains entrainment of circadian rhythms Discontinuation of tasi
VANDA ANNOUNCES POSITIVE RESULTS IN THE SECOND PHASE III STUDY (RESET) OF TASIMELTEON FOR THE TREATMENT OF NON-24-HOUR DISORDER WASHINGTON, January 23, 2013 /PRNewswire/ Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), today announced positive results for the second Phase III study of
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter 2012 Financial Results on February 12, 2013
WASHINGTON, Jan. 22, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVANDA ANNOUNCES POSITIVE PHASE III RESULTS FOR TASIMELTEON IN THE TREATMENT OF NON-24-HOUR DISORDER Tasimelteon is shown to entrain the master body clock as measured by melatonin and cortisol circadian rhythms Tasimelteo
VANDA ANNOUNCES POSITIVE PHASE III RESULTS FOR TASIMELTEON IN THE TREATMENT OF NON-24-HOUR DISORDER WASHINGTON, D.C., December 18, 2012, /PRNewswire/ Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) today announced positive results from the SET (Safety and Efficacy of Tasimelteon) Pha
Read more →VNDAVanda Receives Negative Opinion from CHMP on Fanaptum™ for the Treatment of Schizophrenia
WASHINGTON, Dec. 13, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), announced today that the European Medicines Agency's (EMA) Committee for Medicinal Product for Human Use (CHMP) has issued a negative opinion recommending against approval of Fanaptum™ (oral ilop
Read more →VNDACristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (202) 734-3414 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2012 Results WASHINGTON, D.C.
Senior Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2012 Results November 7, 2012 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and com
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2012 Results
WASHINGTON, Nov. 7, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational re
Read more →VNDAVanda Pharmaceuticals to Present at the Lazard Healthcare Conference
WASHINGTON, Nov. 5, 2012 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will deliv
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2012 Financial Results on November 7, 2012
WASHINGTON, Oct. 17, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDATasimelteon Restores Daily Cortisol Rhythms in Blind Patients with Non-24-Hour Disorder WASHINGTON, D.C. October 15 2012, /PRNewswire/ Vanda Pharmaceuticals (NASDAQ:VNDA), a biopharmaceutical company focused on the devel
Tasimelteon Restores Daily Cortisol Rhythms in Blind Patients with Non-24-Hour Disorder WASHINGTON, D.C. October 15 2012, /PRNewswire/ Vanda Pharmaceuticals (NASDAQ:VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment
Read more →VNDAVanda Pharmaceuticals to Participate in Two September Healthcare Investor Conferences
WASHINGTON, Aug. 23, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will present at two
Read more →VNDAFanapt™ is Granted Market Approval in Israel for the Treatment of Schizophrenia
WASHINGTON, Aug. 9, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that the Israeli Ministry of
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2012 Results
WASHINGTON, Aug. 2, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational re
Read more →VNDACristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (202) 734-3414 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2012 Results WASHINGTON, D.C.
Senior Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2012 Results August 2, 2012 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and comm
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2012 Financial Results on August 2, 2012
WASHINGTON, July 10, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced it will release results for
Read more →VNDAVanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
WASHINGTON, July 5, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Robert Repella, Vanda's
Read more →VNDAMichael Cola Joins the Board of Directors of Vanda Pharmaceuticals WASHINGTON, DC
Michael Cola Joins the Board of Directors of Vanda Pharmaceuticals June 18, 2012 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Michael Cola has joined Vanda s Board of Directors. Mr. Cola will also serve as a member of the Audit Committee of the Board replacing
Read more →VNDASeventy Percent of Totally Blind Individuals With Sleep Complaints Suffer From Chronic Circadian Rhythm Sleep Disorder
BOSTON, June 11, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, announced today that data presented at SLEEP, the 26th
Read more →VNDAVanda Pharmaceuticals to Present at SLEEP 2012 26th Annual Meeting of the Associated Professional Sleep Societies
WASHINGTON, June 4, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that the Company will presen
Read more →VNDAVanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders
WASHINGTON, May 31, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that it will hold its 2012 A
Read more →VNDAVanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
WASHINGTON, May 29, 2012 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that Mihael H. Pol
Read more →VNDAVanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
WASHINGTON, May 22, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, announced today that the Company presented two posters at the Society
Read more →VNDACristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (202) 734-3414 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports First Quarter 2012 Results WASHINGTON, D.C.
Senior Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports First Quarter 2012 Results May 8, 2012 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commerci
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2012 Results
WASHINGTON, May 8, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operational res
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 8, 2012
WASHINGTON, April 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the first quart
Read more →VNDAVanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company WASHINGTON, DC
Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company WASHINGTON, DC, April 16, 2012 /PRNewswire/ Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for centr
Read more →VNDACristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results ROCKVI
Senior Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results ROCKVILLE, MD. February 14, 2012 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical compan
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter 2011 and Full Year 2011 Results
ROCKVILLE, Md., Feb. 14, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced financial and operation
Read more →VNDAInitial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock In Non-24-Hour Sleep-Wake Disorder ROCKVILLE, Md.
Initial Clinical Data Reveal Potential of Tasimelteon to Reset the Body Clock In Non-24-Hour Sleep-Wake Disorder ROCKVILLE, Md., January 26, 2012 /PRNewswire/ Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that tasimelteon was shown for the first time to reset the b
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter 2011 Financial Results on February 14, 2012
ROCKVILLE, Md., Jan. 18, 2012 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth q
Read more →VNDAVanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel
ROCKVILLE, Md., Dec. 13, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Meg
Read more →VNDACristina Murphy Senior Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2011 Results ROCKVILLE, MD.
Senior Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2011 Results November 4, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and com
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2011 Results
ROCKVILLE, Md., Nov. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the
Read more →VNDANeue Website zielt auf häufig vorkommende Schlafstörung bei blinden Menschen ab
ROCKVILLE, Maryland, October 25, 2011 /PRNewswire/ -- - 24sleepwake.com bietet interaktive Werkzeuge und Forschungsupdates zur Unterstützung von Patienten, Freunden und Familien Für die meisten Menschen ist der Ablauf der biologischen Uhr recht gleichförmig, man wacht mit der S
Read more →VNDAUn nouveau site Web consacré à un trouble du sommeil courant chez les individus aveugles
ROCKVILLE, Maryland, October 25, 2011 /PRNewswire/ -- 24sleepwake.com propose des outils interactifs ainsi que les dernières nouvelles de la recherche afin d'aider les patients, leurs amis et familles Pour la plupart des personnes, l'horloge biologique est plutôt régulière : on
Read more →VNDAVanda Pharmaceuticals Appoints Chief Commercial Officer
ROCKVILLE, Md., Oct. 24, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it has named Bob Repella as Senior Vice President, Chief Commercial Officer of the company. Mr. Repella has more than 25 years of experience in the biotech/pharmaceutical
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 4, 2011
ROCKVILLE, Md., Oct. 18, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the third qu
Read more →VNDAVanda Pharmaceuticals to Participate in UBS Global Life Sciences Conference
ROCKVILLE, Md., Sept. 14, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Va
Read more →VNDAVanda Pharmaceuticals Inc. 2011 Corporate Presentation Forward-Looking Statement Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe,
Tasimelteon - Major Depressive Disorder Circadian Mechanism Suspected in Major Depressive Disorder Phase advance theory of depression Diurnal variation of symptoms Light therapy in seasonal affective disorder Tasimelteon: Proof of concept - Positive forced swim test Valdoxan(r):
Read more →VNDAVanda Pharmaceuticals to Participate in Stifel Nicolaus Global Healthcare Conference and Jefferies Fall 2011 Mid-Atlantic Corporate Access Day
ROCKVILLE, Md., Aug. 31, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Van
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2011 Results
ROCKVILLE, Md., Aug. 4, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the
Read more →VNDACristina Murphy Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2011 Results ROCKVILLE, MD.
Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2011 Results ROCKVILLE, MD. August 4, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development
Read more →VNDAVanda Pharmaceuticals Enters into an Exclusive License Agreement with Biotoscana Farma S.A. for Commercialization of Fanapt ™ in Argentina.
ROCKVILLE, Md., August 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Ar
Read more →VNDAEuropean Medicines Agency Accepts Vanda Pharmaceuticals Inc.
ROCKVILLE, Md., July 26, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that the European Medicines Agency (EMA) accepted for evaluation Vanda's Marketing Authorization Application (MAA) for oral iloperidone tablets. Iloperidone is an atypical anti
Read more →VNDAVanda Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 4, 2011
ROCKVILLE, Md., July 20, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the second q
Read more →VNDAVanda Pharmaceuticals Enters into an Exclusive License Agreement with Probiomed S.A. de C.V. for Commercialization of Fanapt™ in Mexico
ROCKVILLE, Md., July 11, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Pro
Read more →VNDAVanda Pharmaceuticals Inc. 2011 Corporate Presentation Forward-Looking Statement Various statements in this release are forward-looking statements under the securities laws. Words such as, but not limited to, believe, ex
Tasimelteon Major Depressive Disorder Circadian Mechanism Suspected in Major Depressive Disorder Phase advance theory of depression Diurnal variation of symptoms Light therapy in seasonal affective disorder Tasimelteon: Positive forced swim test Valdoxan : MT1/MT2 agonist approve
Read more →VNDAVanda Pharmaceuticals to Present at the Jefferies 2011 Global Healthcare Conference
ROCKVILLE, Md., June 2, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that Mihael H. Polymeropoulos, M.D., Vand
Read more →VNDAVanda Pharmaceuticals Reports First Quarter 2011 Results
ROCKVILLE, Md., May 5, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for the
Read more →VNDACristina Murphy Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports First Quarter 2011 Results ROCKVILLE, MD.
Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports First Quarter 2011 Results ROCKVILLE, MD. May 5, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and
Read more →VNDAVanda Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 5, 2011
ROCKVILLE, Md., April 22, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the first q
Read more →VNDAVanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
ROCKVILLE, Md., April 11, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that Novartis Pharmaceuticals Corporation, an affiliate of Vanda's sublicensor Novartis Pharma AG, has initiated a clinical study to evaluate the long-acting injectable (or de
Read more →VNDAVanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression
ROCKVILLE, Md., March 31, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced its plans to initiate a Phase IIb/III clinical trial of tasimelteon in patients with Major Depressive Disorder (MDD). The trial is expected to begin during the second half of
Read more →VNDAVanda Pharmaceuticals Receives Orphan Drug Designation in Europe for tasimelteon
ROCKVILLE, Md., March 8, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that the European Commission (EC) has granted orphan drug designation for tasimelteon, an oral dual melatonin receptor agonist in Phase III clinical trails for Non-24-Hour Sle
Read more →VNDAVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results
ROCKVILLE, Md., Feb. 10, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for th
Read more →VNDACristina Murphy Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results ROCKVILLE, MD.
Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2010 Results ROCKVILLE, MD. February 10, 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused o
Read more →VNDAVanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
ROCKVILLE, Md., Feb. 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth qu
Read more →VNDAVanda Pharmaceuticals Files Shelf Registration Statement
ROCKVILLE, Md., Jan. 31, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced that it has filed a universal shelf regi
Read more →VNDAVANDA PHARMACEUTICALS RECEIVES POSITIVE RULING FROM THE IRS Rockville MD
VANDA PHARMACEUTICALS RECEIVES POSITIVE RULING FROM THE IRS Rockville MD, November 15, 2010. Vanda Pharmaceuticals Inc. (Nasdaq:VNDA) reported today that it has received a private letter ruling (PLR) from the Internal Revenue Service (IRS) regarding certain income tax issues a
Read more →VNDAVanda Pharmaceuticals Appoints Chief Financial Officer
ROCKVILLE, Md., Nov. 12, 2010 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that it has named James Patrick Kelly as Senior Vice President, Chief Financial Officer, Treasurer and Secretary of the Company. Mr. Kelly has more than 18 years of
Read more →VNDAVanda Pharmaceuticals Reports Third Quarter 2010 Results
ROCKVILLE, Md., Nov. 3, 2010 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational resul
Read more →VNDANot For Immediate Release Company Contact: Cristina Murphy Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2010 Results ROCKVIL
Not For Immediate Release Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2010 Results ROCKVILLE, MD. November 3, 2010 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical compan
Read more →VNDAVanda Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 3, 2010
ROCKVILLE, Md., Oct. 28 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the thir
Read more →VNDAVanda Pharmaceuticals Inc.
Tasimelteon Summary Clinical efficacy/safety studies complete Q4 2012 Target NDA filing early 2013 Orphan indication Low R D spend Significant commercial opportunity ($ in millions) 06/30/10 Cash/cash equivalents/ST investments $207.1 ($ in millions) Six Months Ended 06/30/10 Rev
Read more →VNDAVanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
ROCKVILLE, Md., Aug. 26 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder (N24HSWD), a condition experienced primarily by totall
Read more →VNDAVanda Pharmaceuticals Reports Second Quarter 2010 Results
ROCKVILLE, Md., Aug. 5 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced financial and operational results for
Read more →VNDANot For Immediate Release Company Contact: Cristina Murphy Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2010 Results ROCKVI
Not For Immediate Release Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2010 Results ROCKVILLE, MD. August 5, 2010 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company
Read more →VNDAVanda Pharmaceuticals adds former U.S. Surgeon General, Steven Galson, to its Board of Directors ROCKVILLE, MD
Vanda Pharmaceuticals adds former U.S. Surgeon General, Steven Galson, to its Board of Directors ROCKVILLE, MD July 1, 2010 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Dr. Steven Galson, former Acting U.S. Surgeon General, has joined Vanda s Board of Direct
Read more →VNDANot For Immediate Release Company Contact: Cristina Murphy Communications Manager Vanda Pharmaceuticals Inc. (240) 599-4500 cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports First Quarter 2010 Results ROCKVIL
Not For Immediate Release Communications Manager Vanda Pharmaceuticals Inc. cristina.murphy@vandapharma.com Vanda Pharmaceuticals Reports First Quarter 2010 Results ROCKVILLE, MD. May 4, 2010 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company foc
Read more →VNDAVincent Milano to Join the Board of Directors of Vanda Pharmaceuticals ROCKVILLE, MD
Vincent Milano to Join the Board of Directors of Vanda Pharmaceuticals ROCKVILLE, MD April 20, 2010 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), announced today that Vincent Milano, CEO of ViroPharma Incorporated, will join Vanda s Board of Directors. Mr. Milano will replace Bri
Read more →VNDAVanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders ROCKVILLE, MD., March 10/PRNewswire-FirstCall/ Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will hold its 2010 Annu
Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders ROCKVILLE, MD., March 10/PRNewswire-FirstCall/ Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will hold its 2010 Annual Meeting of Stockholders on Thursday, June 3, 2010, in Rockville, Ma
Read more →VNDAVanda Pharmaceuticals Inc. Cowen Healthcare Conference
Occurs almost entirely in subjects who are totally blind and lack the light sensitivity necessary to reset the circadian clock. Orphan Indication Facts Orphan indication granted January 2010 Streamlined development Tax credit / User fees for NDA waived FDA protocol assistance 7 y
Read more →VNDAStephanie R. Irish Acting Chief Financial Officer Vanda Pharmaceuticals Inc. (240) 599-4500 stephanie.irish@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results ROCKVIL
Acting Chief Financial Officer Vanda Pharmaceuticals Inc. stephanie.irish@vandapharma.com Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results ROCKVILLE, MD. February 16, 2010 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company
Read more →VNDAFanapt Launches in the
Fanapt Launches in the U.S. ROCKVILLE, MD, January 11, 2010 Vanda Pharmaceuticals (NASDAQ: VNDA) today announced that Novartis Pharmaceuticals Corporation has launched Fanapt (iloperidone) in the U.S. Fanapt was approved by the U.S. Food and Drug Administration on May 6, 2009
Read more →VNDAVanda Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Exclusive License of Fanapt ROCKVILLE, MD
Vanda Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Exclusive License of Fanapt ROCKVILLE, MD December 1, 2009 Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that the waiting period has expired under the Hart-Scott-Rodino (HSR) Antitru
Read more →VNDANot For Immediate Release Company Contact: Stephanie R. Irish Acting Chief Financial Officer Vanda Pharmaceuticals Inc. (240) 599-4500 stephanie.irish@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2009 Resu
Not For Immediate Release Acting Chief Financial Officer Vanda Pharmaceuticals Inc. stephanie.irish@vandapharma.com Vanda Pharmaceuticals Reports Third Quarter 2009 Results ROCKVILLE, MD. November 2, 2009 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutica
Read more →VNDAVanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt in the U.S. and Canada for the Treatment of Schizophrenia ROCKVILLE, MD
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt in the U.S. and Canada for the Treatment of Schizophrenia ROCKVILLE, MD October 12, 2009 Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) announced today that it has
Read more →VNDAStephanie R. Irish Acting Chief Financial Officer Vanda Pharmaceuticals Inc. (240) 599-4500 stephanie.irish@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2009 Results
Acting Chief Financial Officer Vanda Pharmaceuticals Inc. stephanie.irish@vandapharma.com Vanda Pharmaceuticals Reports Second Quarter 2009 Results FDA GRANTS U.S. MARKETING APPROVAL OF FANAPT (ILOPERIDONE) ROCKVILLE, MD. August 10, 2009 Vanda Pharmaceuticals Inc. (Vanda) (N
Read more →VNDAexv99w1 Figure 1. Schematic Representation of the Molecular Pathway Involved in Regulation of Sleep and Circadian Rhythm Figure 3. Treatment Effect on REM Sleep (A) and Non-REM Sleep (B) in Individuals Who Carried a PER3
A similar genotype effect was observed for rate of accumulation of NREM sleep following treatment with tasimelteon (Figure 3B) In non-5/5 individuals, the midpoint of accumulation of total average NREM sleep (2 hours 21 minutes) was reached faster for those treated with tasimelte
Read more →VNDAVanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders ROCKVILLE, MD., May 29/PRNewswire-FirstCall/ Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will hold its 2009 Annual
Vanda Pharmaceuticals Announces Date of Annual Meeting of Stockholders ROCKVILLE, MD., May 29/PRNewswire-FirstCall/ Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced today that it will hold its 2009 Annual Meeting of Stockholders on Thursday, August 27, 2009, in Rockville, M
Read more →Competitive Position
How VNDA ranks across every disease it competes inCompetitive Position is a premium feature
See how VNDA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial